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Úvod: Rostoucí počet studií ukazuje, že mitochondriální dysfunkce mohou být způsobeny 
některými běžně užívanými léky a sehrávat klíčovou roli v rozvoji jejich nežádoucích účinků. 
Jedním z příkladů je derivát fenolu propofol. Propofol je intravenózní, rychle a krátkodobě 
působící hypnotikum, které se rutinně užívá jak k anestezii v průběhu operačních zákroků, tak 
i k sedaci na jednotkách intenzivní péče. Syndrom propofolové infuze (PRIS) je vzácnou, avšak 
závažnou komplikací podávání léku s velmi vysokou mortalitou. Mezi jeho typické známky 
patří metabolická acidóza, nově vzniklé arytmie, změny na EKG podobné známkám 
pozorovaným u Brugada syndromu, hypertriglyceridémie, horečka, hepatomegalie, 
rhabdomyolýza, srdeční a/nebo renální selhání. Riziko vzniku syndromu se zvyšuje se 
stoupající dávkou a dobou podávání (˃48 hod). Mechanismus vzniku syndromu není dosud 
znám: pilotní studie provedené na animálních modelech naznačují poškození 
mitochondriálního metabolismu. V úvodní části práce byla provedena rešerše všech 153 
publikovaných kazuistik popisujících PRIS a všech dosud provedených experimentálních prací. 
Dalším cílem studie bylo potvrdit hypotézu mitochondriálního poškození pomocí 
prolongované in vitro expozice lidských svalových buněk různým koncentracím propofolu a 
poté měřením jejich mitochondriálních funkcí metodou extracelulárního fluxu. 
 
Metody: Vyhledány byly všechny kazuistiky popisující syndrom propofolové infuze (v období 
let 1990-2014) a provedena byla analýza jak vztahu mezi jednotlivými známkami PRIS a dávkou 
a dobou podávání propofolové infuze, tak i rizikových faktorů zvyšujících pravděpodobnost 
mortality. V in vitro studii byly použity svalové buňky, izolované z kosterního svalu (m. vastus 
lateralis) získaného biopsií pacientů (n=30) v průběhu elektivních operací kyčelního kloubu. 
Buňky byly vydiferencovány v myotuby a poté exponovány 4 koncentracím propofolu 
odpovídajících jeho hladině v plazmě při podávání propofolové infuze při sedaci či anestezii (1, 
2.5, 5 a 10 µg/ml). Po 96 hodinách expozice byl měřen jejich energetický metabolismus pomocí 
XF-24 extracelulárního flux analyzátoru. V průběhu experimentu byla měřena spotřeba kyslíku 
jak bazální, tak po přidání dalších 3 látek: inhibitoru ATPasy, odpřahovače a inhibitoru 
dýchacího řetězce. Z naměřených dat jsme následně určili bazální spotřebu kyslíku (OCR), 
obrat ATP, leak protonů přes vnitřní mitochondriální membránu a kapacitu dýchacího řetězce. 
Kapacita β-oxidace mastných kyselin byla měřena jak metodou extracelulárního fluxu (jako 
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etomoxirem inhibovatelná OCR po přidání odpřahovače a palmitátu), tak pomocí radioaktivně 
značeného palmitátu. Pro detailnější otestování funkce dýchacího řetězce byla měřena 
respirace po přidání specifických substrátů a inhibitorů pro jednotlivé komplexy (I, II, III a IV). 
Aktivity jednotlivých komplexů byly navíc měřeny spektrofotometricky.  
 
Výsledky: Meta-analýza dat získaných ze 153 publikovaných kazuistik PRIS ukázala více než 
>51% mortalitu. Faktory spojenými s vyšší mortalitou byly dávka a délka podávání propofolové 
infuze, horečka a kraniotrauma. Srdeční selhání a metabolická acidóza se objevily časně po 
začátku podávání propofolu a byly závislé na dávce, zatímco výskyt arytmií, změn na EKG a 
rhabdomyolýzy se zvýšil s dobou podávání propofolové infuze, nezávisle na dávce. V in vitro 
studii byl porovnáván efekt propofolu s kontrolními buňkami rostoucími v čistém mediu i s 
buňkami exponovanými buď pouze lipidovému nosiči propofolu (Intralipidu) anebo směsi 
mastných kyselin odpovídajících složení Intralipidu (55% kyselina linoleová, 27% kyselina 
olejová a 10.5% kyselina palmitová). Viabilita buněk a bazální spotřeba kyslíku byla ovlivněna 
pouze nejvyššími koncentracemi propofolu (10 µg/ml), zatímco již nejnižší testované 
koncentrace snížily maximální kapacitu dýchacího řetězce. Expozice propofolem způsobila 
mírné odpřažení vnitřní mitochondriální membrány, nezávislé na dávce propofolu. Jednotlivé 
komplexy dýchacího řetězce nebyly inhibovány. Nejvýznamnější abnormitou, navozenou 
propofolem, byla inhibice oxidace mastných kyselin na 36%, resp. 33% bazálních hodnot 
(expozice 2.5, resp. 10 µg/ml propofolu). 
 
Závěr: Diagnóza PRIS může být obtížná, protože některé z typických příznaků PRIS mohou 
často (>95%) chybět (hypertriglyceridémie, horečka, hepatomegalie, srdeční selhání) a jiné 
(např. arytmie) se objevují později. Klinické projevy PRIS naznačují poškození 
mitochondriálního metabolismu. Provedená in vitro studie prokázala, že propofol snižuje 
maximální respirační kapacitu dýchacího řetězce a způsobuje výraznou inhibici β-oxidace 









Introduction: Increasing number of reports reflect that mitochondrial dysfunction can be 
induced by some of the commonly used drugs and can play a key role in the development of 
their adverse effects. One of these drugs is a phenol derivative propofol. Propofol is an 
intravenous, fast and short-acting hypnotic agent, routinely used either for induction and 
maintenance of anaesthesia during surgery, or for sedation in intensive care units. Propofol 
infusion syndrome (PRIS) is a rare, but serious adverse effect of the drug with a very high mortality. 
Typical features of the syndrome include metabolic acidosis, arrhythmias, ECG changes that are 
similar to those of Brugada syndrome, hypertriglyceridemia, fever, hepatomegaly, 
rhabdomyolysis, cardiac and/or renal failure. The risk of the syndrome increases with raising dose 
and duration of propofol administration (˃48 hours). The mechanism of the syndrome is still 
unknown: pilot studies performed on animal models are suggestive of its mitochondrial origin. In 
the first part of the study, we performed the analysis of 153 published case reports and all 
experimental studies related to PRIS. Another aim of the study was to test hypothesis of propofol-
induced mitochondrial damage by in vitro exposure of human skeletal muscle-derived cells to a 
range of propofol concentrations and then assessment of mitochondrial functions by Extracellular 
Flux Analysis. 
Methods: We searched for all case reports describing PRIS (published between 1990 and 2014) 
and we analysed both the relationship between signs of PRIS and the rate and duration of propofol 
infusion, and risk factors for mortality. In the in vitro study, we used human skeletal muscle cells 
that were isolated from skeletal muscle (m. vastus lateralis) obtained from patients (n=30) 
undergoing hip replacement surgery. Cells were differentiated into myotubes and exposed to a 
range of 4 propofol concentrations resembling its levels in human plasma during propofol infusion 
at sedation or anaesthesia (1, 2.5, 5 a 10 µg/mL). After 96 hours of exposure, energy metabolism 
was assessed using XF-24 Extracellular Flux Analyzer. During experiment, we measured oxygen 
consumption rate (OCR) at baseline and after addition of three agents: inhibitor of ATPase, 
uncoupler and inhibitor of respiratory chain. The measurement enabled us to determine basal 
OCR, ATP production, proton leak and maximal respiratory capacity of the respiratory chain. The 
capacity of fatty acid oxidation was measured using both Extracellular Flux Analyzer (by etomoxir-
induced inhibition of OCR after addition of palmitate and uncoupler) and radioactively labelled [1-
14C] palmitate. In addition, we measured respiration after addition of specific substrates and 
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inhibitors for individual complexes of the respiratory chain (complex I, II, III and IV). Activities of 
individual complexes were also measured spectrophotometrically. 
 
Results: Meta-analysis of 153 case reports about PRIS showed more than >51% mortality. Risk 
factors associated with high mortality were dose and duration of propofol infusion, fever and 
craniotrauma. Cardiac failure and metabolic acidosis occurred early after initiation of propofol 
infusion and are dose-dependent, whilst arrhythmias, ECG changes and rhabdomyolysis appeared 
more frequently after prolonged propofol infusion, irrespective of dose. In the in vitro study, we 
compared effect of propofol on myotubes with control cells incubated in fresh medium or exposed 
to either lipid vehicle (Intralipid) or non-esterified fatty acids (NEFA) mixture resembling Intralipid 
composition (55% of linoleic acid, 27% of oleic acid and 10.5% of palmitic acid). Cell viability and 
basal oxygen consumption were influenced by only the highest propofol concentration (10 
µg/mL), whilst the lowest concentration already caused decrease of maximal respiratory capacity. 
Exposure to propofol caused a mild uncoupling of inner mitochondrial membrane, irrespective of 
propofol dose. Individual complexes of the respiratory chain were not inhibited. The most 
significant propofol-induced abnormality was inhibition of fatty acid oxidation to 36% and 33% of 
baseline values (exposure to 2.5 and 10 µg/mL of propofol, respectively). 
 
Conclusion: Diagnosis of PRIS may be challenging as some of its typical features are often (>95%) 
missing (hypertriglyceridemia, fever, hepatomegaly, cardiac failure) and others (e.g. arrhythmias) 
appear later. Clinical features of PRIS are suggestive of its mitochondrial origin. Our in vitro study 
showed that propofol decreases maximal respiratory capacity and causes profound inhibition of 










1. Introduction: mitochondria  
Mitochondria are cellular organelles generating energy in the form of ATP molecules, 
essential to maintain homeostasis and survival of cells1, sometimes signed as “powerhouse of the 
cell”. Mitochondria have also another important functions including calcium and iron 
homeostasis, synthesis of pyrimidines and steroids, calcium signalling or thermogenesis and fever 
response2. 
Term of mitochondria. In 1886, Richard Altmann firstly observed the organelles under 
microscope and described them as granula inside the cell3. He called them “bioblasts” because he 
believed that these “blasts” are the living units within the cell.  In 1898, Carl Benda stained these 
organelles by crystal violet and saw that they are of thread-shape but other time they appear like 
granules4. He coined the term “mitochondrion” from the Greek words “mitos” (=thread) and 
“chondrion” (=granule).  
Structure of mitochondria. Mitochondria look like membrane-coated organelles, but their 
construction is more complex. In addition to the external mitochondrial membrane forming the 
shape of mitochondria, inside is also an inner mitochondrial membrane, which is shrouded in 
numerous “cristae”3 (see Figure 1). Between both membranes, intermembrane space is located. 
Internal compartment matrix is area surrounded by inner membrane. Enzymes of respiratory 
chain are incorporated into the inner mitochondrial membrane, whilst tricarboxylic acid ([TCA]; 
citric acid; Krebs) cycle, fatty acid oxidation etc. are performed inside matrix. Mitochondrial shape 
and size may differ according to cell line (e.g., in hepatocytes and fibroblasts mitochondria have 
3-4 μm in length and approximately 1 μm in diameter and have a typical oblong "sausage-like” 
shape)3. Cristae founded in inner mitochondrial membrane can also have a different shape 
(lamellar or tubular). However, the number of mitochondria and cristae are the most important 
parameters for function. The number of mitochondria in one cell vary in different cell types and 
ranges from a few hundred to thousands (e.g. the liver cell contains approximately 800 
mitochondria, while the human oocyte counts to ˃ 100,000 mitochondria)3. Similarly, number of 
cristae vary in different cell lines. For example, mitochondria in muscle cells, have high-folded, 
lamellar cristae with a large surface area leading to high respiratory rate3.  
  Chemiosmotic theory. In 30’s, there were first attempts to isolate mitochondria, and, in 
early 50’s, it was well-described that mitochondria contain the enzymes of the TCA cycle, fatty 
acid oxidation and oxidative phosphorylation. In 1961, Peter Mitchell proposed his chemiosmotic 
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hypothesis suggesting that synthesis of ATP in respiring cells is generated via the electron 











Figure 1. Electron microscopy picture of human heart muscle mitochondria. Scale bar: 0.5 µm. 
Krajčová et al., 20185. 
Energy production. Mitochondria can utilize both pyruvate from glucose and fatty acids as 
fuel. Pyruvate and fatty acids are transported across the inner mitochondrial membrane and then 
converted to the metabolic intermediate Acetyl Coenzyme A (Acetyl-CoA), either by enzyme 
pyruvate dehydrogenase or enzymes of fatty acid oxidation, both located in the mitochondrial 
matrix. Acetyl-CoA is then oxidized as a substrate for TCA cycle in series of chemical reactions 
resulting in a production of reduced coenzymes nicotinamide adenine dinucleotide (NADH) and 
flavin adenine dinucleotide (FADH2) and CO2 as a waste molecule.  According to chemiosmotic 
theory, electrons from reduced coenzymes (NADH and FADH2) generated during catabolic 
pathways (glucose metabolism, TCA cycle, fatty acid oxidation), are transferred along electron 
transfer chain (ETC) consisting of 4 complexes of respiratory chain (I, II, III, IV) in the inner 
mitochondrial membrane to final acceptor oxygen3. The reducing equivalents (electrons) enter 
the ETC at two sites: complex I (NADH: ubiquinone oxidoreductase) or complex II (succinate: 
ubiquinone oxidoreductase) and undergo sequential oxidation reduction reactions. Complex I and 
II reduce ubiquinone (coenzyme Q) to ubiquinol. Complex III (ubiquinone: cytochrome c 
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oxidoreductase) couples the oxidation of ubiquinol to cytochrome c reduction. Complex IV 
(cytochrome c: oxygen oxidoreductase) catalyses the oxidation of cytochrome c, reducing 
molecular oxygen and producing water. Energy released during redox states is used for pumping 
the protons across the inner mitochondrial membrane from matrix into the intermembrane space 
at three sites: complex I, III, and IV. Inner mitochondrial membrane is impermeable for protons 
and they accumulate in intermembrane space creating electrochemical gradient. The enzyme F1F0-
ATPase, which is translocated in the inner mitochondrial membrane, allows protons to diffuse 
back into the matrix through its molecule. During the process, ATPase undergoes conformational 
changes leading to formation of adenosine triphosphate molecule from adenosine diphosphate 
and inorganic phosphate. In summary, proton-motive force is used for ATP synthesis. The process 
is called oxidative phosphorylation, and, during physiological conditions, couples respiration with 
ATP production. Fatty acids transport and oxidation. Fatty acids, as fuel for energy production, 
firstly need to be transported through outer and inner mitochondrial membrane into the matrix, 
where enzymes of fatty acid oxidation (β-oxidation; FAO) are located. Long chain-fatty acids (e.g. 
palmitate) need for the transport carnitine shuttle. Fatty acids are esterified with Coenzyme A to 
form acyl-CoA, when they enter the cell. Coenzyme A cannot cross the mitochondrial membranes 
to enter the matrix. Acyl-CoA therefore undergoes reaction with carnitine, by enzyme CPT-1 
(carnitine palmitoyl transferase 1) resulting in formation of acylcarnitine and CoA. Acylcarnitine 
then gets into the intermembrane space by Carnitine-acylcarnitine translocase and crosses the 
inner membrane, where it transfers acyl group onto CoA, which is freely available in mitochondrial 
matrix. The reaction is catalysed by CPT-2 (carnitine palmitoyl transferase 2) and its product – acyl-
CoA enters fatty acid oxidation in matrix. Fatty acid oxidation includes a series of reactions 
catalysed by 4 enzymes leading to production of Acetyl-CoA. Of note, through the process, FADH2 
is also generated which enters respiratory chain by electron transfer flavoprotein (ETF) 
dehydrogenase. Short-chain and medium-chain fatty acids can enter mitochondria as 
independently on carnitine. They are activated in the mitochondrial matrix where short-chain and 
medium-chain acyl-CoA synthetases are located.  
In conclusion, defects of energy production can be caused by inhibition of substrate 
pathways, inhibition of FAO and inhibition in electron transfer chain, either by defects of 
complexes I, II, III, IV and ETF dehydrogenase/or electron carriers: coenzyme Q or cytochrome c.  
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2. Drug-induced mitochondrial dysfunction 
Increasing number of reports reflect that mitochondria, either as a primary or secondary 
target to drugs6, and their dysfunction, can play a key role in drug-induced adverse effects7. Drugs 
can affect mitochondria either directly (by uncoupling or inhibition of electron transport chain, 
inhibition of mitochondrial transport pathways, inhibition of fatty acid oxidation or fatty acid 
uptake, the citric acid (tricarboxylic acid; Krebs) cycle, mitochondrial DNA transcription, protein 
production)2 or indirectly (by increasing reactive oxygen species production leading to 
mitochondrial DNA mutation, membrane depolarization and decreased antioxidant production)6. 
For example, adriamycin-induced mitochondrial cardiomyopathy is a well-known complication of 
this commonly used chemotherapeutics caused by interference with mitochondrial metabolism 
via inhibition of ATP production (by uncoupling of oxidative phosphorylation) and production of 
reactive oxygen species8. Liver toxicity is a side effect of valproic acid, widely used antiepileptic 
drug9. It was observed in an in vitro study, that sodium valproate decreases oxygen consumption 
rate and mitochondrial membrane potential10. Statins, a class of drugs used for 
hypercholesterolaemia treatment, are well-known for their two important side effects, elevation 
of liver enzymes and myotoxicity, which could vary from mild myopathy to serious 
rhabdomyolysis11. Recent studies are suggestive of their impact on mitochondrial function, 
causing directly complex III inhibition12 or coenzyme Q10 deficiency13. Statins inhibit HMG-CoA 
reductase producing mevalonate, a precursor of both cholesterol and coenzyme Q1014. 
Amiodarone, a class III antiarrhythmic agent causing micro-vesicular steatosis of the liver is 
associated with inhibition of fatty acid oxidation in mitochondria15,16. Antibiotics, such as 
tetracyclines or chloramphenicol, impair mitochondrial respiration17 by inhibition of fatty acid 
oxidation18 or mitochondrial protein synthesis and decreasing ATP production19. Acetylsalicylic 
acid, one of the non-opioid analgesics, caused inhibition of fatty acid oxidation20 in patients who 
developed Reye‘s syndrome. Metformin is a widely used oral antidiabetics from class of 
biguanides, which inhibits activity of complex I of respiratory chain leading to decreased ATP 
synthesis in mitochondria21.  
One of the agents which are suggestive to have an impact on mitochondrial metabolism is 
phenol derivative propofol, which is one of the most commonly used drugs in anaesthesia. Its rare 
but fatal complication “propofol infusion syndrome” is known from 1990 and includes metabolic 
acidosis, cardiac failure, arrhythmias, rhabdomyolysis, renal failure, hypertriglyceridemia and 
fever22. Previous animal studies and its clinical symptoms are suggestive of its mitochondrial 
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origin, but exact mechanism remains unknown. Specific treatment doesn’t exist, and mortality is 
high.  
 
3. Propofol in clinical practice 
Propofol is an intravenous sedative agent used for an induction and maintenance of 
anaesthesia and sedation in the intensive care units (ICUs) from 1980’s23,24. It is a short acting 
lipophilic hypnotic agent with a chemical structure of an alkylphenol derivative (2,6-
diisopropylphenol; see Figure 2), which is administered as 1 or 2% solution in 10% Intralipid 
infusion. Propofol acts by potentiating γ-aminobutyric acid type A (GABAA) receptors to 
achieve the sedative hypnotic effect25. It has become widely used both in children and adult 
patient population26, due to its multiple favourable effects including rapid onset of action, short 
half-life and less incidence of postoperative adverse effects (e.g. nausea and vomiting) in 
comparison with previously commonly used anaesthetics as thiopental and methohexital27,28. 
Moreover, it has been shown that propofol is a suitable replacement for etomidate for sedation 
in cardiac surgery patients29 and it has also gained popularity in the population of neurosurgical 
patients with trauma head injury due to its ability to maintain or reduce intracranial pressure, 
while maintaining an adequate cerebral perfusion pressure30. Propofol had been generally 
considered safe and efficacious31, but in the early 1990’s fatal complications after its 




Figure 2. Chemical structure of propofol (2, 6 – diisopropylphenol). 
 
4.  Chemical structure and properties of propofol  
Propofol is chemically described as 2,6-diisopropylphenol, a simple phenol substituted 
with two isopropyl groups positioned on each side of a hydroxyl group (see Figure 2)34. Its pure 
substance has a slightly yellowish colour and it has an oil consistence at room temperature. The 
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molecule of propofol is insoluble in aqueous solution because of its highly lipophilic benzene ring 
and isopropyl side groups35. Due to its high lipophilicity propofol was firstly administered as 1% 
active agent dissolved in solution containing 16% polyethoxylated castor oil (Cremophor EL), but 
this formulation was soon withdrawn as the stabilizing agent was found to cause anaphylactic 
reactions36. Nowadays, propofol is commercially available as 1 or 2% (10 or 20 mg/mL, resp.) active 
agent 2,6-diisopropylphenol dissolved in 10% Intralipid emulsion37, which consists of  soybean oil 
(100 mg/mL), egg yolk lecithin (12 mg/mL) and glycerol (22.5 mg/mL)35. Due to this Intralipid 
vehicle, which also serves as a parenteral nutritional agent, propofol is famed for its “milky” 
appearance. The pH of the emulsion is adjusted with sodium hydroxide to around 7.0 – 8.5 for 
optimal emulsion stability35. Lipid vehicle can be conducive to bacterial growth38. Thus, propofol 
infusion also contains 0.005% of the chelating agent disodium edetate (EDTA), which acts as an 
antimicrobial agent39.  
 
5. Pharmacokinetics and pharmacodynamics of propofol 
Propofol is a phenol derivative which is structurally and chemically unrelated to 
barbiturates and other previously used anaesthetic agents40. Anaesthetic properties of propofol 
were discovered in 197341,42 by Imperial Chemical Industries in the United Kingdom (UK) 
investigating the sedative effects of phenol derivatives in animal models34.  The early study in 
humans demonstrated that propofol it the effective and safe induction agent with pain after 
injection as the only known side-effect43. During 1980’s, it became very popular in anaesthesia 
and intensive care because of its favourable pharmacokinetic profile including particularly rapid 
onset, short duration of action and fast recovery. Its pharmacokinetics involves a three-
compartment model consisting of plasma, rapidly and slowly equilibrating tissues44. Propofol has 
a fast onset and short duration of action due to its rapid penetration of the blood-brain barrier40. 
Its initial distribution half-life is very short (around 2–8 min)45. Propofol rapid distribution to the 
central nervous system is followed by its fast redistribution to inactive tissue depots (muscle and 
fat tissue) and then it is slowly returned from these peripheral compartments into the blood40. 
Loss of consciousness is achieved within 20 to 40 seconds after intravenous administration46. After 
initial bolus, propofol concentration in human plasma rapidly decreases because of the fast 
redistribution from brain to peripheral tissues46 and because of its rapid elimination45. Propofol 
administration is characterized by lack of accumulation on repeated boluses and lack of excitatory 
effects on induction and during maintenance and recovery47. Propofol is rapidly metabolized in 
the liver to inactive glucuronide, sulphate conjugates and corresponding quinol metabolites, 
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producing water-soluble compounds which are excreted mainly by the kidneys45,48,49. It also 
undergoes 4-hydroxylation by cytochrome P450 to 2,6-diisopropyl-1,4-quinol, which can also 
undergo glucuronide conjugation and excretion in the urine49. Clearance of propofol is extremely 
high and recovery occurs rapidly after drug discontinuation50. Rate of recovery is even ten times 
higher than e.g. that of thiopental51. These pharmacokinetic properties make propofol suitable 
and popular for short procedures when sedation is needed for only a few minutes50. Renal and 
hepatic diseases have no clinically significant effect on the metabolism of propofol48. Propofol has 
significant pharmacodynamic effects in cardiovascular system as it causes 15-25% decrease in 
blood pressure and systemic vascular resistance without a compensatory increase in heart rate, 
and cardiac output is decreased by 20%48. Propofol can cause profound bradycardia, possibly 
through resetting of the baroreceptor reflex and rarely even make asystole48. Propofol 
administration influences also respiratory system – the only bolus can produce apnoea of variable 
duration (30 to ≥60 seconds) and suppression of laryngeal reflexes48. In the central nervous 
system, propofol causes a dose-dependent decreased level of consciousness and reduces cerebral 
blood flow, intracranial pressure, and cerebral oxygen consumption. Propofol is therefore often 
used in cases requiring decrease in intracranial pressure, e.g. patients with trauma head injury.  
Propofol action is related to the major inhibitory neurotransmitter GABA (γ-aminobutyric 
acid) in the central nervous system. GABAA receptors are located in the postsynaptic membrane 
and mediate neuronal inhibition in brain52. Propofol binds to GABAA receptors potentiating the 
inhibition and resulting in its sedative and hypnotic effect53. The binding to the receptors induces 
opening of chloride channels and increases chloride conductance across the neuron resulting in 
the hyperpolarization of the cell membrane52. In addition, propofol inhibits glutamate receptors54 
and reduces extracellular glutamate levels55.  
 
6. History of propofol infusion syndrome (PRIS) 
6.1 PRIS in the paediatric population 
The first case report of fatal complication after propofol administration was documented 
in Denmark in 199032. 2-year old girl with upper respiratory infection received propofol infusion 
at dose of 10 mg/kg per hour for duration of 4 days. The child developed severe metabolic acidosis, 
hypotension and multiple organ failure of unknown etiology leading to death. Authors related 
these fatal complications to propofol infusion. Two years later, Parke et al. published similar cases 
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in the United Kingdom33. Five children, aged between 4 weeks and 6 years, developed serious 
complications leading to death after propofol administration. All children were admitted to 
intensive care unit for upper or lower respiratory infection and intubated within 24 hours from 
admission. In all cases, propofol was used for sedation at the average dose of 7.4-10 mg/kg per 
hour for duration of 66-115 hours. Every patient subsequently developed increasing metabolic 
acidosis followed by hyperlipidaemia and bradyarrhythmia proceeding to progressive myocardial 
failure that was resistant to resuscitation. Some of them suffered also by fever, hepatomegaly, 
pulmonary oedema, acute renal failure, hypocalcaemia or hyperkalaemia. Echocardiography and 
necropsy showed no evidence of structural heart disease or cardiomyopathy. Furthermore, there 
was no evidence of viral myocarditis, Reye’s syndrome or sepsis. Propofol infusion was considered 
the presumable cause of the death33. In June 1992, Committee on Safety of Medicine in the United 
Kingdom issued a warning against propofol use for sedation in the population of paediatric 
patients, although there was no evidence of a direct effect of propofol or its vehicle in children 
receiving propofol infusion56,57. Investigation of Food and Drug Administration (FDA) in United 
States did not find a direct link between propofol administration and death of these paediatric 
patients, but further study was conducted58,59. A few weeks later, the first case of successful 
treatment of these serious adverse effects was described60. 20-month old child with acute 
epiglottitis was administered with propofol infusion at the dose of 5-10 mg/kg per hour for 
duration of 56 hours. The third day of propofol administration the child developed metabolic 
acidosis, hyperlipidaemia, bradycardia, hypotension and oliguria. Laboratory blood test revealed 
high concentration of creatine kinase and muscle biopsy showed necrosis. Bradycardia rapidly 
proceeded to asystole, which successfully responded to pharmacological treatment. Veno-venous 
hemodiafiltration was initiated and after that replaced by peritoneal dialysis.  The patient 
gradually recovered and was discharged from the hospital60. In following years, number of case 
reports describing these propofol complications increased61,62 and manufacturer warned against 
propofol use as a sedative agent in intensive care units in paediatric patients in 199458. Several 
authors had still doubts about whether propofol could be the cause of the death in these cases 
and considered propofol to be safe drug63, but other similar reports of propofol-induced death 
continued to be documented in literature64–68.  
In 2001, the unpublished randomized controlled trial (reviewed by FDA) observed 28-day 
mortality in 327 patients sedated by propofol in paediatric ICUs in United States. Results showed 
increased mortality in patients with propofol sedation in comparison with control group: mortality 
was about 11% for group of patients receiving 2% propofol, and 8% for group of patients receiving 
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1% propofol. Patients with non-propofol sedation had about 4% mortality. FDA and Canadian 
Health Board issued a warning against propofol use for long-term sedation in children69. Short-
term administration was generally still considered safe but few children developed these adverse 
effects even after several hours, 2.5 hours70 and 5 hours67.  
6.2 PRIS in the adult population  
Although the syndrome was initially documented solely in children, few reports were 
published in the population of adult patients71–73. In 1996, Marinella et al. described a case of 30-
year-old woman with acute respiratory failure, who needed a mechanical ventilation and propofol 
sedation74. After only 2 hours she developed metabolic acidosis and blood test showed increased 
lactate level. After discontinuation of propofol infusion, laboratory values normalized and patient 
recovered and remained without any consequences74. In 2000, Perrier et al. reported the first case 
of death caused by propofol infusion in adults73. 18-year-old patient with trauma head injury 
developed metabolic acidosis, hyperkalaemia, elevated levels of creatine kinase and arrhythmias 
progressing to asystole that was resistant to treatment73. Similar cases in adults were 
subsequently described71,72,75. Cremer et al. published in The Lancet a landmark paper of seven 
cases of PRIS in the neurosurgical ICU and was the first to highlight that the cumulative dose of 
propofol was the main risk factor for its development72. In 2002, guidelines for population of adult 
patients were issued76. Jacobi et al. recommended to avoid propofol administration in 
concentrations higher than 83 µg/kg/min because of increased risk of cardiac arrest in adults76. 
Authors also recommended to monitor patients receiving propofol for unexplained metabolic 
acidosis or arrhythmias76. In 2006, the FDA updated the labelling information and limited the 
maximum dose of propofol recommended for sedation to 4 mg/kg per hour77. At the same time 
European regulatory authorities suggested that patients should be monitored for metabolic 
acidosis, hyperkalemia, rhabdomyolysis or elevated creatine kinase level and signs of heart failure. 
In case of development of these signs they recommended reduction or discontinuation of 
propofol58,78.  
 
7. Definition of PRIS 
In 1998, propofol infusion syndrome was defined by Bray et al.65. Authors summarized all 
cases concerning adverse effects of propofol used for sedation documented in literature within 
this year and described clinical and laboratory signs of the syndrome. In most cases propofol was 
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used to provide sedation during mechanical ventilation. The syndrome was defined as: (1) a 
sudden, or relatively sudden, onset of a marked bradycardia, resistant to treatment and 
progressing to asystole, and also the appearance of one of the following symptoms: (2) the 
presence of lipaemic plasma; (3) a clinically enlarged liver or histological evidence of fatty 
infiltration of the liver found at autopsy; (4) the presence of metabolic acidosis (with a base deficit 
˃ 10 at least once in a patient’s arterial blood sample); (5) the presence of muscle involvement 
with evidence of rhabdomyolysis or myoglobinuria65. In following years, many patients with PRIS 
developed tachycardia instead of bradycardia. Therefore, some authors suggested modification 
of Bray’s definition and used “the presence of heart failure and arrhythmias” as one of the signs 
of PRIS58,79,80. 
A current view on the syndrome is quite different from previous Bray’s definition in 
90’s. In our first publication in Critical Care, we analyzed data from 153 patients with PRIS from 
case reports and case series published between 1990 and 2014 and we looked at the presence 
of individual signs of the syndrome81.  In many cases, patients developed only mild unexplained 
acidosis and elevation of creatine kinase, sometimes with worsening of acute kidney injury and 
arrhythmia, but other features of PRIS were often missing82–86. In some of reported cases, mild 
unexplained acidosis was even the only sign of possible PRIS development, which completely 
disappeared after propofol withdrawal74. Because symptoms can occur in any combination and 
order and can range from the very mild to severe in each individual patient, it is very difficult to 
determine a precise definition of PRIS.  
 
8. Epidemiology of PRIS 
PRIS is a rare complication of propofol administration and its incidence is still unknown. It 
is well known that development of PRIS depends on the presence of risk factors e.g. propofol 
infusion rate or duration72,79,81. In 1998, Bray et al. observed 33% incidence of PRIS in a group of 
paediatric patients receiving propofol at the mean dose higher than 4 mg/kg per hour for a 
minimum of 48 hours65. In 2001, Cremer et al. reported the incidence of PRIS in adult head-injured 
patients72. PRIS occurred in 17% of patients receiving propofol at the dose of 5 to 6 mg/kg per 
hour and in 31% of patients receiving propofol at the dose greater than 6 mg/kg per hour72. 
Cravens et al. recorded the occurrence of metabolic acidosis in the group of adult patients 
undergoing radiofrequency ablation87. 24% patients who were administered with propofol at the 
high-dose of 20 mg/kg per hour for a duration of 7 hours developed metabolic acidosis.  Authors 
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selected solely the cases, where propofol agent was considered the only possible cause of 
acidosis87. In 2008, Fong et al. proposed results of their retrospective analysis of all case reports 
with PRIS published in MEDLINE system between 1989 and 200522. Authors searched for the 
reports where patients developed at least one of the clinical symptoms of PRIS. Of 1139 patients 
with suspected PRIS, 30% were fatal22. Higher mortality was associated with young age, male sex 
and concomitant administration of vasopressors or presence of cardiac abnormalities, metabolic 
acidosis, renal failure, hypotension, rhabdomyolysis or hypotension22. In 2009, Smith et al. showed 
6% incidence of the syndrome in population of patients with severe head trauma injury88. 
According to the results, concomitant use of vasopressors was associated with development of 
PRIS in this cohort88. Roberts et al. analysed the group of 1017 critically ill adult patients receiving 
propofol at least for 24 hours83. The incidence of PRIS slightly exceeded 1% and in most cases 
(91%) PRIS development was associated with the concomitant vasopressor administration83. Iyer 
et al. analysed the group of patients admitted to ICU with refractory status epilepticus who 
received propofol89. 45% patients developed features of PRIS and mortality of the cohort was 
about 6%89. In 2014, Schroeppel et al. examined the cohort of 207 patients with trauma brain 
injury and found 2.9% incidence of PRIS85.  
Although the number of published case reports of PRIS worldwide was less than 200 until 
2018, we believe that in fact the syndrome occurred in many cases that were unrecognized or 
never documented by clinicians.  
 
9. Clinical manifestation and laboratory findings of PRIS 
In 2008, Fong et al. reviewed all reported cases of PRIS and analysed its most common 
clinical and laboratory signs22.  Most frequent features included the following: cardiac failure or 
arrhythmias (43,7%), hypotension (34%), rhabdomyolysis (27%), hepatic insufficiency (24,1%), 
renal insufficiency (23,5%), metabolic acidosis (20,1%), hypoxia (17,5%), hyperthermia (11,6%) 
and dyslipidaemia (5,3%)22.  
Cardiovascular system. The most frequent changes seen in PRIS were related to the 
cardiovascular system. Arrhythmias: in 2008, Bray et al. defined the presence of bradycardia that 
is resistant to treatment and proceeding to asystole as a criterion essential for diagnosis of PRIS65. 
In following years, some patients with PRIS developed ventricular or supraventricular tachycardia, 
right bundle branch block or atrial fibrillation instead of bradycardia79,80. Electrocardiographic 
changes: in 2006, Vernooy et al. analysed data from previously published study in the group of 
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neurological patients with PRIS90 and described their electrocardiographic changes91. Six of the 
seven patients with PRIS developed electrocardiogram (ECG) changes preceding malignant 
arrhythmias and sudden cardiac death after several hours91. The first described abnormality on 
ECG was elevation of ST-segments (in precordial leads V1-V3) that was similar to ECG pattern of 
Brugada syndrome. Subsequently, all six patients developed prolonged QT interval, idioventricular 
rhythm, ventricular tachycardia or ventricular fibrillation. All six patients died within 10 ± 12 hours 
after initiation of ECG changes. Propofol rate was 7.9 ± 1.2 mg/kg/hour at the time of ECG changes. 
Study also documented case report of 15-year-old child, who developed rhabdomyolysis, renal 
insufficiency, ST elevations in right precordial leads and inversion of T waves on ECG after several 
days of propofol administration91. In that case, propofol infusion was immediately withdrawn with 
normalization of ECG (except persisting T waves inversions) and patient survived91. Vernooy et al. 
concluded that development of coved-type ST-segment elevation (similar to that present an ECG 
pattern of Brugada syndrome) in the right precordial leads is the first warning sign of electrical 
instability and imminent sudden cardiac death related to PRIS91. Authors recommended ECG 
monitoring during high-dose propofol administration. In case of Brugada-like pattern on ECG, 
physicians should be alert to danger of serious cardiac rhythm disturbances91. Weiner et al. 
reported the case of critically ill patient who developed Brugada ECG pattern after high-dose 
propofol infusion92 (see Figure 3). When ECG pattern was recognized, the propofol was withdrawn 
and the ECG pattern resolved. The patient was discharged home with no signs of arrhythmia. In 
summary, various ECG changes were documented in many cases of patients with PRIS. According 
to Robinson et al., arrhythmias might develop even in the absence of profound acidosis or 
myocardial failure93.   
Metabolic changes. Metabolic acidosis was present in most of PRIS cases. According to 
Koch et al., lactic acidosis might be an early stage of PRIS94. Although significant lactic acidosis 
frequently occurred within a few hours after propofol initiation67,70,74,82,92,94–98, some patients 
developed either only mild metabolic acidosis93,99 or PRIS occurred even without acidosis100,101. 
Most patients with PRIS had hyperlipidemia33,68 which was considered an early sign of PRIS102. 
Hypertriglyceridemia is thought to be secondary to altered lipid kinetics in liver due to Intralipid 
infusion103. Gottschling et al. described that short-term propofol administration at the standard 
dose and rate might significantly increase serum triglycerides and pancreatic enzyme levels in 


















Figure 3. Electrocardiogram (ECG) of the patient who developed Brugada-like pattern after high-
dose propofol infusion92. A) ECG 2 hours after initiation of propofol administration showing sinus 
tachycardia with diffuse ST segment elevation with a rSr’ pattern in V1-V2. B) ECG 13.5 hours after 
the initial electrocardiogram with development of Brugada pattern with coved ST segment 
elevation in V1 and V2 (indicated by black arrows). C) ECG 2 days after propofol discontinuation: 
ST segment elevation resolved leaving only a rSr’ pattern similar to the initial electrocardiogram. 
Adapted from Weiner et al., 201092. 
 
Liver. Hepatomegaly is quite often and well described clinical feature of 
PRIS33,65,95,100,105,106. Histological examination showed micro-vesicular fatty liver infiltration33 and 
10% zone III necrosis with fat changes similar to those seen in acetaminophen poisoning107. In 




Muscle injury and rhabdomyolysis. Rhabdomyolysis, skeletal and cardiac muscle injury 
might be presented in PRIS and are associated with specific laboratory findings, e.g. elevated 
serum creatine kinase levels, troponin I or potassium concentration111. Histological tissue 
examination in patients with PRIS revealed a focal necrosis in skeletal60,112 or cardiac muscle113.  
Renal system. Acute renal injury might occur in PRIS as the consequence of rhabdomyolysis 
and myoglobinuria33,67,89,100,109,114–123. Histological findings in the patients with PRIS showed acute 
tubular necrosis and presence of myoglobin casts in kidney tubules90,124. Depending on the degree 
of injury, serum creatinine levels might be elevated in blood samples56,68,86,91,92,100,109,112,114,115,117–
119,125. Green discoloration of the urine is other known adverse effect of propofol treatment and is 
caused by propofol metabolites (4-sulfate and 1- or 4-glucuronide conjugates of 2,6-diisopropyl-
1,4-quinol)126.  Although urine discoloration has been described in many cases of 
PRIS106,107,115,116,127, it can occur also in patients not developing the syndrome126.  
Another laboratory findings observed in patients with PRIS were hyperbilirubinemia60, 
coagulopathy or hyperphosphatemia116. In 2001, Wolf et al. performed detailed biochemical 
analyses of patient with PRIS that revealed increased levels of malonyl-carnitine and C5-
acylcarnitine suggesting propofol impact on fatty acid oxidation68. In the study from 2004, 
Withington et al. described an increased levels of acylcarnitine intermediates (especially medium-
chain fatty acids) in patient with PRIS116.  
 
10. Pathophysiology of PRIS 
In accordance with previous studies, propofol is suggestive to cause an impairment of 
electron transfer chain and fatty acid oxidation in mitochondria, but exact mechanism remains 
unknown. 
10.1 Inhibition and uncoupling of electron transfer chain  
According to the pilot animal in vitro studies, propofol is thought to act as an inhibitor of 
electron transport chain128–131 and probably a mild uncoupler of inner mitochondrial 
membrane130,132. In early studies, Branca et al. briefly exposed isolated rat and heart liver 
mitochondria to various concentrations of propofol128,129,132. Isolated rat liver mitochondria were 
exposed to a range of propofol concentrations up to 100 μmol/L, which led to a linear dose-
dependent reduction of respiratory chain capacity and transmembrane potential, but no 
impairment of ATP synthesis up to 75 μmol/L propofol128,132. Complex I was more sensitive to 
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propofol than complex II and, in addition, propofol (at range of 25–400 μmol/L) caused proton 
leak through the inner mitochondrial membrane130. In mitochondria isolated from rat hearts, 
inhibition of ATP synthesis was observed only at high dose concentrations (>300 μmol/L) of 
propofol129.  
In an in vitro study performed on isolated perfused guinea pig hearts, supratherapeutic 
propofol concentrations (50–200 μmol/L) caused a delay in myoglobin desaturation and 
cytochrome c reduction after exposure to ischaemia, consistent with inhibition of the respiratory 
chain, but not with uncoupling of inner mitochondrial membrane131. Decreased activity of 
cytochrome c oxidase (complex IV) was independently revealed in the skeletal muscle biopsies 
obtained from two patients who developed PRIS67,107. Another study found significantly reduced 
activities (of complex II+III and complex IV) of the respiratory chain in the skeletal muscle in the 
patient who died of PRIS133. 
Vanlander et al. was the first who emphasized on the structural similarity of propofol with 
strongly lipophilic Coenzyme Q (CoQ), which works as an electron-carrier in the inner 
mitochondrial membrane transferring electrons from complexes I and II to complex III133.  In a 
series of experiments performed on rats (combining in vivo and in vitro exposure to propofol), 
authors demonstrated that propofol in therapeutic levels probably incorporates into the inner 
mitochondrial membrane, where interacts with CoQ molecule: possibly by electron acceptance 
from complexes I and II instead of CoQ and blocking electron transfer further to complex III, whilst 
much higher concentrations of propofol are needed to block the activities of individual 
complexes133. To confirm this hypothesis, they tested 3 minutes pre-incubation of propofol and 
then supplementation with CoQ. The results showed that inhibition of complex II+III by propofol 
was preventable with CoQ supplementation133. In the very high concentration, propofol caused 
inhibition of complex IV activity of the respiratory chain133. 
10.2 Inhibition of fatty acid oxidation  
Another proposed mechanism of PRIS is an impairment of fatty acid metabolism, 
formulated by Wolf et al.68,134 and Withington et al.116 The authors found accumulated 
intermediates of fatty acid oxidation and increased plasma concentrations of acyl-carnitines in 
children with PRIS68,116,134. The levels normalized after cessation of propofol infusion suggesting a 
propofol-induced defect of fatty acid metabolism135. 
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Animal study performed on rabbits showed an inhibition of the transport of fatty acids into 
mitochondria probably by propofol-induced inhibition of carnitine-acyl transferase I136. This 
enzyme is activated by adenosine monophosphate-activated kinase (AMPK). If propofol interferes 
with signalling function of Coenzyme Q133, it may attenuate the activation of fatty acid oxidation 
by AMPK, but the activity of this enzyme has been increased in the myocardium of propofol-
sedated rabbits137. PRIS was also associated with a ketogenic diet138. Prolonged propofol infusion 
seemed to be a crucial factor in the impairment of fatty acid oxidation: in the patient receiving 
propofol infusion (at the dose of 4.1–6.6 mg/kg per hour) plasma C4-carnitine species elevated 
steadily over the period of 5 days134.  
In summary, previous in vitro studies observed an acute effect of propofol exposure and 
mitochondrial metabolism was assessed after only several minutes of incubation. On contrary, 
propofol infusion syndrome mostly occurs after a prolonged administration (˃48 hours)72,76,134. To 
induce a demonstrable effect after such a short exposure, propofol concentrations used in acute 
experiments need to be much higher than those found in human plasma (up to 10 µg/mL) during 
propofol anaesthesia139 or sedation140,141.  In extremely high concentrations, propofol mostly 
caused direct inhibition of respiratory chain complexes or uncoupling of inner membrane. The 
recent landmark paper of Vanlander et al. focused on the structural similarity of propofol molecule 
with Coenzyme Q133, which needs to be further examined together with propofol-induced 
impairment of fatty acid metabolism.   
 
11. Risk factors and prevention of PRIS 
Risk factors for PRIS include prolonged propofol infusion, critical illness, low carbohydrate 
intake, hepatic dysfunction, catecholamine administration72, glucocorticoids, systemic 
inflammation, cytokine production, young age, subclinical mitochondrial disease, lean body mass 
index142 and head-injury124. According to Cremer et al., head-injured patients in neurosurgical ICUs 
are at particular risk for PRIS development, because high anaesthetic doses of propofol are often 
required in these patients to control intracranial hypertension rather than to simply maintain 
sedation124. In addition, the frequent use of vasopressors, which are supposed to act as triggering 
factor, are used to maintain an acceptable cerebral perfusion pressure72. Cremer et al. suggested 
to avoid propofol infusion at the rate higher than 5 mg/kg/hour for long-term sedation in ICU 
patients72. In 2002, the Society of Critical Care Medicine in alliance with the American College of 
Chest Physicians published guidelines warning that prolonged use (˃48 hours) of high doses of 
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propofol (˃66µg/kg/min) may be associated with development of lactic acidosis, bradycardia and 
lipaemia in children, and infusions of ˃83µg/kg/min could be associated with increased risk of 
cardiac arrest in adults. 115. Although, the prolonged high-dose propofol infusions are typical for 
development of PRIS, the syndrome was described also in patients administered short-term 
propofol infusions74,94,96,118. Liolios et al. advised to be aware of the potential occurrence of the 
syndrome even when high-dose of propofol infusions are used for short time118. In 2006, Merz 
described the first case of PRIS-induced death, when patient was administered by propofol at the 
low infusion rate143. According to Kumar et al., body mass index and body habitus may also play a 
role in the volume of distribution of propofol and may reach toxic levels in lean patients142.  
 
12. Treatment of PRIS 
Up to now, specific treatment of PRIS doesn’t exist. The therapy is based on the supportive 
care including fluid resuscitation, sodium bicarbonate infusion and transvenous pacing. 
Nonetheless, many patients with PRIS diagnosis die and mortality of the syndrome remains 
high22,69. On the contrary, several procedures of successful treatment were described in the last 
two decades60,107,114,116,117,127. In 1992, Barclay et al. successfully used hemodiafiltration 
subsequently replaced by peritoneal dialysis in the case of 20-month-old child with PRIS60. It was 
the first reported case when child with PRIS survived60. In 1996, Cray et al. successfully treated 
PRIS patient by plasmapheresis followed by continuous veno-venous hemofiltration107. Following 
cases reported other successful methods: extracorporeal membrane oxygenation144, 
hemoperfusion116 or hemodialysis116,117. In 2004, Culp et al. reported a case report of 13-year-old 
child with PRIS in cardiogenic shock who successfully recovered after treatment by extracorporeal 
membrane oxygenation (ECMO)144. Further case reports of successful ECMO support were 
documented in literature110. In 2010, Guitton et al. described the case of adolescent PRIS patient 
who developed cardiocirculatory arrest110. ECMO was used for the treatment, cardiocirculatory 
function improved rapidly and patient fully recovered110. According to the authors, ECMO should 
be considered in cases of cardiocirculatory failure110. In 2010, Da Silva et al. described a case report 
of 4-year-old boy in whom previously described methods (haemodialysis, hemoperfusion or 
ECMO) was limited because of severe hemodynamic instability127. The patient was treated the 
partial-exchange blood transfusion continued by veno-venous haemodialysis when he became 
haemodynamically stable127. The treatment was successful, and authors recommend to use this 
procedure as a bridge during a period of severe hemodynamic instability127. In many other cases 
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with PRIS survivors, authors believe that the development of the syndrome was averted simply by 
the early recognition of PRIS, immediate cessation of propofol infusion and, if necessary, its 
replacement by another anaesthetic, e.g. midazolam74,96.  
13. Meta-analysis of 153 published PRIS case reports and case series  
In our publication “Propofol infusion syndrome: a structured review of experimental 
studies and 153 published case reports“ (reported in Critical Care, 2015) we analyzed data from 
153 patients case reports and case series published between 1990 and 201481.   
13.1 Aims of the study 
We primary aimed to determine the relationship of propofol administration with PRIS 
clinical and laboratory outcomes and to analyze the factors increasing mortality81. The secondary 
aim was to find a link between the clinical presentations with proposed cellular mechanisms and 
to describe trends over time81. 
13.2 Methods and statistical analysis 
We searched for all cases about PRIS published between 1990 and 2014. Consent for 
the study was not required, as the reports had been previously published81. A three-stage 
search method was performed when looking for all articles81. Firstly, we started with a general 
keyword search on the PubMed database using terms “Propofol-infusion syndrome” which 
yielded 275 articles81. We sorted all the articles related to PRIS and obtained the full-texts.  
We worked without any language limitation and included articles in English, German, Spanish, 
Chinese, Danish and Norwegian81. Google Translate was used to extract the data from articles 
in Scandinavian languages and the English abstract only for one article in Chinese81. Secondly, 
we searched references of these papers for further articles fulfilling the eligibility criteria 
described above but not identified during our original search81. Finally, we also included 
reports of unexpected metabolic acidosis and arrhythmia in patients on propofol published 
prior to the 1998 definition of PRIS81. This resulted in the total number of 94 manuscripts 
reporting on 153 patients with suspected PRIS81. 
In these papers we specifically searched and extracted data describing patients’ 
demographic characteristics (sex and age), underlying diseases (traumatic brain injury, 
respiratory infection, status epilepticus, other neurological cause or others), average propofol 
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rate (mg/kg per hour) and duration (hours), unexplained metabolic acidosis, arrhythmias, 
other ECG changes, cardiac failure, acute respiratory distress syndrome, hypotension, acute 
kidney injury (AKI; any report of oliguria, anuria or increased creatinine), rhabdomyolysis (or 
elevated creatine kinase or myoglobin), lipaemia (or increased plasma triglycerides), liver 
damage and unexplained fever81. We considered a sign as being present if the original case 
report authors described it as a sign of PRIS: in most case reports this causation is suspected 
if a sign occurred or worsened after propofol administration and disappeared or improved 
after discontinuation of propofol administration81. We did not analyze concomitant 
medication (vasopressors and steroids) as these data were missing in >50 % of published 
cases81. In each case, the outcome was defined as “survived” (if the patient was reported to 
recover from PRIS) or “died”, regardless of the report authors’ opinion on the cause of death81.  
In order to describe trends over time, simple linear regression was used for statistical 
analysis81 and cases were divided into three groups (n = 27, 53 and 72, resp.) demarcated by the 
years of publication: 2001 (the year of banning prolonged propofol infusion in children and the 
acceptance of the existence of PRIS in adults) and 2006 (the year when the safety limit of 4 mg/kg 
per hour was recommended)81. Multiple logistic regression was used to analyze risk factors for 
mortality and calculate the influence of every single independent variable on mortality81. All 
calculations were performed using Stata Software (version 13.1; Stata Corp. Ltd., USA), and p 
values <0.05 were considered significant.  
13.3 Results  
13.3.1 Changes of features of PRIS over time 
90 % patients developed PRIS as a complication of non-procedural sedation in ICUs and 
remaining 10 % as a complication of propofol use during anesthesia81. The duration of infusion in 
reported cases of PRIS raised over time and the mean propofol infusion rate decreased, resulting 
in an overall decrease in the cumulative propofol dose leading to PRIS81. Mean age of patients in 
reported cases increased over time, and this trend was apparent even if pediatric cases were 
excluded from the analysis81. There was no change in the underlying disease of patients with PRIS 
over time, but the incidence of some reported signs of PRIS changed81 (see Figure 4). Arrhythmia, 
other ECG changes, hypertriglyceridemia and fever occurred with less frequency over time81. 
Metabolic acidosis remained the most common symptom of PRIS with a constant incidence at 














Figure 4. Frequency of symptoms in reported cases of PRIS over time. Data presented as means, 
vertical bars are 95 % confidence intervals. Krajčová et al., 201581. 
 
13.3.2 Influence of propofol infusion rate and duration on signs of PRIS 
Propofol infusion rate significantly influenced the frequency of fever (which occurs in <5 % of 
patients with an infusion rate <4 mg/kg per hour, but in >40 % with an infusion rate above 8 mg/kg 
per hour) (see Figure 5)81. There is a trend to similar dose dependency for cardiac failure and 
metabolic acidosis, which both occur more frequently with the dose above 4 mg/kg per hour81. 
Other signs occur in similar frequencies across the range of propofol infusion rates. When looking 
at the influence of the duration, arrhythmia and other ECG changes occur more frequently after 
48 hours of infusion (see Figure 6)81. The incidence of rhabdomyolysis and hypertriglyceridemia 
increase after 96 hours of administration. On the contrary, metabolic acidosis occurs more 
















Figure 5. Relative frequency (y axis) of symptoms in patients divided into four quartiles of reported 
propofol infusion rate. Data presented as means, vertical bars are 95 % confidence interval. 












Figure 6. Relative frequency (y axis) of symptoms of PRIS in patients divided into four quartiles of 
reported propofol infusion duration. Data presented as means, vertical bars are 95 % confidence 
intervals. Krajčová et al., 201581. 
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13.3.3. Factors influencing mortality in published cases of PRIS 
PRIS continues to be reported in the literature in both adult and paediatric population without 
a clear trend to a reduction81. Mortality was higher than 51%81 and decreased over time from 74% 
before 2001, to 64 % between 2001 and 2006, and to 32% in cases reported after 200681. 
Multivariate logistical regression performed on 128 cases with complete datasets identified higher 
dose, longer duration of infusion, development of fever and the presence of TBI as factors 
associated with increased mortality of PRIS81. 
14. Aims and hypotheses 
Experimental data from our meta-analysis from 153 published case reports suggested that 
early, dose-dependent signs of PRIS (metabolic acidosis and cardiac failure) may be caused by 
inhibition or uncoupling of electron transfer chain, whilst late, time-dependent signs (arrhythmias, 
ECG changes and rhabdomyolysis) can be caused by inhibition of fatty acid oxidation and fatty 
acids accumulation after prolonged administration81. 
In the in vitro experiments, we aimed to test long-term propofol effect (at concentrations 
resembling its levels in human plasma during sedation or anaesthesia) on mitochondrial functions 
in human skeletal muscle-derived cells. Firstly, we hypothesized that mitochondrial functions are 
affected by one of the following substances: 
1) propofol agent alone (2,6-diisopropylphenol), or 
2) lipid vehicle Intralipid/or non-esterified fatty acids (NEFA) mixture resembling Intralipid 
composition contained in the propofol infusion, or 
3) the combination of both substances 
Further aims were focused on detailed mechanism of propofol-induced mitochondrial 
impairment. We hypothesized that propofol:   
1) leads to a dose-dependent uncoupling of the inner mitochondrial membrane resulting in 
the reduced production of ATP, dysfunction and muscle damage and possible 
overproduction of heat 
2) causes the reduction of spare respiratory capacity 
3) causes the direct inhibition of one of the complexes of the electron transfer chain leading 
to the reduction of ATP production 




15.1 Study subjects 
Skeletal muscle cells were isolated from biopsies obtained from patients (n = 30; age, 71.8 
± 7.1; body mass index, 28.5 ± 4.8) undergoing hip replacement surgery at the Department of 
Orthopedic Surgery of Královské Vinohrady University Hospital in Prague (for more information 
see Table 1). Muscle cells were obtained by open technique during surgery. Patients more than 
18 years of age, who were given non-propofol anesthesia (e.g. midazolam, etomidate), were 
eligible for the study. Patients receiving propofol during surgery as well as patients with history of 
known mitochondrial disorders were excluded. In addition, for [1-14C] palmitate experiments, we 
obtained vastus lateralis samples under local anesthesia from five healthy volunteers by needle 
biopsy technique (Bergström technique)145 in the Department of Pharmaceutical Biosciences at 
the University of Oslo. This part of study was performed in cooperation with laboratory group of 
professor Arild Rustan from University of Oslo. The study protocols were approved by respective 
research ethics boards in both institutions. All patients provided a prospective written informed 
consent. 
 
15.2 Biopsy of m. vastus lateralis: open technique vs. Bergström technique 
 In our previous work, we compared two techniques of biopsy of musculus vastus lateralis 
obtained from orthopaedic patients146. During the study, the surgeon was asked to gain two 
muscle samples from the same subject (n=6)146. When vastus lateralis muscle was exposed during 
the surgery, one sample was taken by open technique using a scalpel or scissors and the second 
sample from the same muscle using 5 mm Bergström needle attached to a suction catheter146. 
The surgeon involved in the study was trained in the use of Bergström needle. Further processing 
of both samples was identical. In that study, we prepared muscle tissue homogenates and, after 
that, we analyzed global mitochondrial parameters in both groups146. We did not find any 
significant differences in mitochondrial functional indices  between needle and open biopsy 
techniques in human skeletal muscle homogenates146. Therefore, we believe that different 
technique of biopsy had no impact on mitochondrial function in our experiments with propofol 
performed on cell culture. 
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BMI Medical history 
1 F 72 165 83 30.5 OA, hypercholesterolemia 
2 F 72 172 83 28.1 
OA, hypertension, hypercholesterolemia, 
hypothyreosis 
3 F 70 164 64 23.8 
OA, hypercholesterolemia, spondylosis, 
spondyloarthrosis, nephrolithiasis 
4 F 77 150 86 38.2 OA, hypertension, hypothyreosis 
5 F 67 162 78 29.7 
OA, hypertension, ischemic heart disease, Parkinson's 
disease 
6 M 60 180 79 24.4 OA, hypothyreosis, diabetes mellitus, trombofilia 
7 F 73 168 83 29.4 OA, hypertension, diabetes mellitus 
8 F 71 171 103 35.2 
OA, hypertension, hypothyreosis, ischemic heart 
disease 
9 F 80 175 78 25.5 NOF#, hypertension, chronic ischemic heart disease 
10 M 73 172 86 29.1 
NOF#, hypertension, diabetes mellitus, Parkinson 
disease 
11 F 67 169 88 30.8 OA, hypothyreosis, obesity, hypersomnia 
12 M 80 174 60 19.8 
hypertension, OA - reoperation after hip replacement 
surgery 
13 F 59 160 85 33.2 NOF#, hypertension 
14 F 66 158 50 20.0 NOF#, hypertension, dyslipidemia, bronchial asthma 
15 F 80 158 60 24.0 
OA, hypertension, paroxysmal atrial fibrillation, 
chronic ischemic heart disease, chronic renal 
insufficiency, dyslipidemia 
16 M 60 178 80 25.3 
NOF#, hypertension, anxiety-depressive disorder, 
diabetes mellitus, ischemic heart disease, chronic 
renal insufficiency 
17 F 82 160 60 23.4 OA, hypertension 
18 F 77 166 87 31.6 
OA, arterial hypertension, rheumatoid arthritis, 
hypothyreosis, dyslipidemia 
19 F 71 176 80 25.8 NOF#, hypertension, hyperlipidemia 
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20 F 68 180 118 36.4 
OA, hypertension, obesity, hyperlipidemia, 
hypothyreosis 
21 F 83 153 80 34.2 
OA, hypertension, chronic kidney disease, 
dyslipidemia, rheumatoid arthritis 
22 M 61 178 110 34.7 
OA - reoperation after hip replacement surgery, 
hypertension, dyslipidemia 
23 F 84 154 80 33.7 
NOF#, OA, hypertension, ischemic heart disease, 
glaucoma 
24 M 80 171 66 22.6 
OA, ischemic heart disease, atrial fibrillation, chronic 
kidney disease, hypertension, hyperlipidemia 
25 F 72 158 64 25.6 OA, thyroiditis 
26 M 72 181 80 24.4 OA, hypertension 
27 F 76 158 73 29.2 
OA, genu valgum, diabetes mellitus, hypertension, 
hyperlipidemia 
28 F 68 166 82 29.8 
OA, osteoporosis, dyslipidemia, chronic back pain, 
insomnia 
29 F 67 162 74 28.2 OA 
30 M 65 178 94 29.7 OA, hyperlipidemia 
 
Table 1. Detailed characteristics of study subjects on biopsy day. OA = osteoarthritis of the 
hip, NOF# = neck of femur fracture. Krajčová et al., 2017147. 
15.3 Transport of muscle samples 
At least   ̴150 mg of skeletal muscle tissue was used for isolation of satellite cells according 
to protocol of Thompson et al.148. Immediately after biopsy, muscle sample was inserted into 50 
mL falcon tube with pre-cold “Transport Medium” which consisted of Dulbecco’s Modified Eagle’s 
Medium with 5.56 mM glucose, 1 mM pyruvate, 3.7 mM glutamine and phenol red (Thermo Fisher 
Scientific, Inc., MA, USA).  The medium was supplemented with antibiotics (1% solution of 100 
U/mL penicillin and 100 µg/mL streptomycin) and antimycotics (0.1% fungizone) to prevent 
contamination of cells. Biopsy sample was then transferred from operating room to the laboratory 




15.4 Cell culture isolation and cultivation of myoblasts 
Satellite cells were subsequently isolated and cultured as previously described149.  Firstly, 
skeletal muscle tissue was transferred to Petri dish and weighted on analytical scale. After that, 
connective tissue, fat and vessels were removed under microscope with forceps and scissors as 
much as possible. Muscle tissue (150-250 mg) was then transferred into new Petri dish with fresh 
and sterile “Transport Medium” placed in laminar box. Sterile forceps and scissors were used for 
other steps of isolation procedure. Muscle tissue was firstly carefully minced with scissors into fine 
fragments at room temperature. Medium with floating tissue fragments was then pipetted from 
Petri dish into 50 mL falcon tube and diluted with Hank’s balanced salt solution to obtain large 
volume. Skeletal muscle fragments were then centrifuged (350 xg, 25°C) for 5 minutes. After that, 
supernatant was cautiously discarded with vacuum aspirator, pellet with tissue fragments was 
rinsed with colourless Hank’s balanced salt solution and centrifuged again. The step was repeated 
2-3 times until the colour of solution was clear. After last centrifugation, supernatant was 
aspirated, and 0.25% Trypsin/0.68% Collagenase solution was added to the pellet with fragments. 
Cells were subsequently dissociated by incubation in the solution in a shaking water bath at 37°C 
for 30 minutes. Fetal bovine serum containing protease inhibitors (α1-antitrypsin, α2-
macroglobulin) was then added to stop dissociation by inhibition of trypsin activity. Next step for 
isolation of skeletal muscle cells was pre-coating of all dissociated cells on uncoated Petri dish as 
non-coated surface is preferentially used for adhesion by fibroblasts cells, in comparison with 
skeletal muscle-derived cells which prefer to growth on collagen or gelatine-coated surface.  
Therefore, dissociated cells were pre-plated in pre-warmed “Growth Medium” consisting of 
Dulbecco’s Modified Eagle’s Medium supplemented with 15% fetal bovine serum, 5.56 mM 
glucose, 1 mM pyruvate, 1% solution of 100 U/mL penicillin and 100 µg/mL streptomycin, 0.05 
µg/mL fungizone, 0.4 µg/mL dexamethasone, 0.5 mM L-glutamine on uncoated Petri dish at 37°C 
in the atmosphere of 5% CO2 for 60 minutes to remove fibroblasts. Gelatine-coated flasks were 
simultaneously prepared for attachment and growth of myoblasts. Bottom of flasks was coated 
by a small amount of liquid gelatine solution (1-2 ml per 25 cm2 flask), which was then closed and 
incubated in 37°C in 5% CO2. After 30 minutes of incubation, gelatine was removed by aspirator 
and opened flasks with unscrewed lid were left to dry in sterile laminar box at room temperature. 
After pre-plating on uncoated Petri dishes, muscle fragments were subsequently carefully 
transferred into gelatine-coated flasks and cultured in “Growth Medium” at 37 °C in a humidified 
atmosphere of 5 % CO2. After 24 hours, 10 ng/mL of epidermal growth factor, 1 ng/mL of 
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fibroblast growth factor and 10 µg/mL of insulin were added. The “Growth Medium” was changed 
every 2 or 3 days.  
Rate of proliferation. Human myoblasts are rapidly growing and dividing cells with the 
average doubling time of 24-36 hours150. In our previous study, we exposed human skeletal muscle 
cells to different glutamine levels in culture media (0; 100; 200; 300; 500; 5000 µM) and observed 
its effect on cell bioenergetics and proliferation149 (see Figure 7). Surprisingly, supra-physiological 
concentrations of glutamine (5000 µM) as recommended by many protocols for in vitro cell 
cultures151–154, including human myoblasts155, did not bring any additional benefit in terms of 
myoblast proliferation149. Since cells had a high rate of proliferation at 500 µM glutamine, which 
is normal level in human plasma149, we preferred to cultivate myoblasts in medium with this lower 









Figure 7. Proliferation rate of human myoblasts in relation to glutamine concentration in the 
media. Mean number of cells formed from a single cell at day 0. Krajčová et al., 2015149.  
 
The cell line is growing on the bottom of flasks or dishes in a monolayer. Growth of cell 
culture is typically divided into 3 phases (see Figure 8): initiation with short lag phase, when cells 
adapt to new conditions and don’t grow; log phase, when growth of cells begins, and number of 
cells is increasing exponentially; phase of plateau, when cells slow down and stop to grow. In this 
stationary period, cells reach a high density and have no space to divide and grow because cell 
monolayer covers the most of the surface of flask bottom. At this time, cells switch into the phase 
of “contact inhibition”156, when stop proliferating upon contact formation.  Cell crowding, 















Figure 8. Simplified scheme of growth rate of cell culture.   
 
Therefore, upon 80-90% confluency, cells were passaged and seeded into new gelatine-
coated flasks, plates or Petri dishes. During subculturing, trypsin-EDTA solution was used as 
dissociation agent for release of myoblasts attached to the bottom of flask. Old culture medium 
was discarded without disturbing of cell monolayer prior to addition of trypsin-EDTA. Cells were 
subsequently rinsed with Dulbecco’s Phosphate-Buffered Saline (DPBS) without calcium and 
magnesium (Thermo Fisher Scientific, Inc., MA, USA) to remove the rest of FBS which could 
inactivate trypsin. Small amount of trypsin was then added into flask with cells and incubated for 
3-5 minutes in 37°C until it was possible to visualize under microscope that almost all cells were 
floating in trypsin solution. Growth medium supplemented with FBS was then added to stop 
trypsin activation. Cells were manually counted with haemocytometer and small aliquot of cell 
suspension was added to new gelatine-coated flask. Seeding density was at least 3500 cells/per 
cm2 according to recommendation for human skeletal muscle cells158. During trypsinization, 
floating cells are of round shape. Few hours after cells settle down to the bottom of flask and 
attach gelatine-coated surface, they typically change the shape from round to fibrous and 
























Figure 9. Cell culture of myoblasts and myotubes.  Myoblasts in growth medium (A) and  
myotubes in differentiation medium (B) under binocular inverse microscope and appearance of 
myoblasts (C) and myotubes (D) stained for desmin (AB 907 rabbit anti–desmin polyclonal 
antibody [Millipore, Billerica, MA, USA]) under confocal microscopy. Krajčová et al., 2015149.  
 
15.5 Differentiation into myotubes 
Myotubes differentiated from myoblasts were used for all experiments according to Aguer 
et al.155 as they are generally considered an in vitro model of human skeletal muscle. When 
myoblasts reached   ̴ 90% confluency, “Growth Medium” was replaced by “Differentiation 
Medium” consisted of Dulbecco’s Modified Eagle’s Medium containing reduced concentration of 
serum to stop growth of cells and initiate the process of differentiation and fusion into myotubes. 
We used 2% horse serum in medium supplemented with 1% solution of penicillin and 
streptomycin, 25 mM Glucose and 10 µg/mL of insulin. After 7 days, cells were differentiated into 




15.6 Indirect immunofluorescence and confocal microscopy 
We used indirect immunofluorescence and confocal microscopy to confirm the purity of 
cell line155. We stained both myoblasts and myotubes. Cells (myoblasts) were grown on gelatine-
coated coverslips until they reached 80% confluency. Firstly, they were fixed with 4% 
paraformaldehyde. The coverslips were then washed four times in DPBS for 5 min (placed on the 
orbital shaker; speed 80 rpmi) and subsequently permeabilized with 0.5 mL of 0.1 % saponin for 
10 min. Cells were then washed three times again in PBS, labelled with primary antibody rabbit 
anti-desmin AB907 (dilution 1:50, 1:100, 1:200; Millipore, Billerica, MA, USA) and incubated in the 
covered humid chamber for 60 minutes.  After that, cells coverslips were washed with solution of 
0.05% Tween and DPBS and incubated with Goat Anti-Rabbit IgG H&L secondary antibody (Alexa 
Fluor® 488; ab150077; dilution 1:200; Abcam plc, Cambridge, UK) for 60 min at room temperature. 
Finally, the rinsed coverslips were fixed on glass slides using Prolong GOLD with DAPI (4´,6´-
diamidino-2-phenylindole) and sealed with nail polish. Indirect immunofluorescence was 
performed using confocal microscopy LEICA TCS SP5 (see Figure 9, part C).  In case of myotubes, 
the same procedure with all described steps was performed but cells were differentiated into 
myotubes (by incubation in Differentiation Medium for 7 days) on coverslips prior to staining (see 
Figure 9, part D).  
 
15.7 Cell culture exposure to various conditions 
After 7 days of differentiation, cells were cultivated in different conditions. Individual 
components of propofol infusion were tested on cells both separately and in combination. Each 
condition was performed in triplicates or tetraplicates.  
15.7.1 Duration of exposure 
Previous experiments performed on animal models tested propofol effect on 
mitochondria in high doses and after acute exposure128–130,132. Since the risk of PRIS increases with 
prolonged duration of propofol administration, we decided to test propofol on human skeletal 
muscle cells after long-term exposure.  In addition, in our meta-analysis of 153 published PRIS case 
reports we found that some signs (e.g. rhabdomyolysis) occurred more frequently after propofol 
infusion longer than 96 hours. Therefore, we chose the duration of 4 days (= approximately 96 




15.7.2 Myotubes exposed to different concentrations of propofol and Intralipid 
Chemical structure of propofol is a strongly hydrophobic alkylphenol derivative 2,6-
diisopropylphenol. Due to its high lipophilicity, 1% propofol is administered soluted in 10% 
intralipid emulsion. Therefore, we decided to test propofol agent as well as its lipid vehicle. The 
cells were cultured in four different concentrations (1, 2.5, 5 and 10 µg/mL) of propofol (2,6-
diisopropylphenol; Sigma-Aldrich, USA) corresponding to its clinical concentrations in human 
plasma during propofol infusion (anaesthesia and sedation) or in medium containing 10% 
Intralipid (Intralipid® 10%; Fresenius Kabi, Germany). Control groups of cells were, in parallel, 
incubated either in fresh medium alone or ethanol which was used for propofol stock preparation 
(see below).  
15.7.3 Myotubes exposed to different concentrations of propofol and non-esterified 
fatty acids (NEFA) 
In human plasma, triglyceride levels are elevated after Intralipid infusion159. Triglycerides 
are subsequently hydrolyzed releasing free fatty acids160,161. Considering this Intralipid in vivo 
effect, we incubated cells also in NEFA mixture resembling fatty acids composition of Intralipid 
(with the ratio of fatty acids: 55% of linoleic acid, 27% of oleic acid and 10.5% of palmitic acid)162 
at the total concentration of 500 µM. In the experiments, cells were cultivated in two different 
concentrations of propofol alone (2.5 and 10 µg/mL). Another groups of cells were exposed to 
medium containing same concentrations of propofol (2.5 and 10 µg/mL) combined with NEFA 
mixture as well. Control groups of cells were cultured either in fresh medium or medium 
supplemented with NEFA.  
15.8 Preparation of reagents for experiments 
15.8.1 Preparation of propofol stock 
Prior to all experiments, propofol stock was prepared. Commercially produced propofol is 
available as 1 or 2% (10 or 20 mg/mL) active agent 2,6-diisopropylphenol37 dissolved in 10% 
Intralipid emulsion. For our experiments, 2,6-diisopropylphenol (Sigma-Aldrich, Corp., St. Louis, 
MO, USA) was used as an active agent. The stock was prepared fresh before every experiment or 
addition of propofol into medium to cell culture. Propofol was firstly diluted in purified ethanol 
and then in “Differentiation Medium” to obtain final concentration of 1 mg/per mL. After that, 
propofol stock was added into myotubes whilst diluted in their “Differentiation Medium” to obtain 
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lesser concentrations. Different aliquots of the stock were pipetted to cell culture medium to gain 
various levels of propofol, but we wanted to maintain the same concentration of ethanol vehicle 
in each sample at the same time. Therefore, we prepared a range of propofol stocks (1 mg 2,6-
diisopropylphenol/mL), where ethanol amount was always adjusted to obtain the same final 
ethanol concentration when pipetted into the medium of every group of cells. By this way, we 
obtained cell groups incubated at the range of propofol concentrations, where each of them was 
diluted in the same amount of ethanol. Resulting ethanol concentration in cell culture was very 
low (˂ 0.01 %), which should not be toxic for cells. We confirmed this also by cell viability tests 
(see below).  
15.8.2 Preparation of Intralipid vehicle and NEFA  
10% Intralipid® emulsion (Fresenius Kabi, AG, Germany) was used for all experiments. 
NEFA (linoleic acid, oleic acid, palmitic acid) were prepared as previously described163,164 at the 
total concentration of 500 µM. Concentration of fatty acids was calculated using commercial kit 
(NEFA Randox). Fatty acids were stored in -20°C for maximum of 2 months. 
15.8.3 Preparation of substrates, uncouplers and inhibitors  
All reagents were obtained from Sigma-Aldrich, Corp., St. Louis, MO, USA. Substrates 
(malate, glutamate, succinate, ascorbate and N,N,N′,N′-tetramethyl-p-phenylenediamine [TMPD]) 
and adenosine diphosphate (ADP) were diluted in distilled water and stored in -20°C for maximum 
of 2 months. Duroquinol was prepared always fresh prior to experiment from its oxidized form 
duroquinone as previously described165. ATPase inhibitor oligomycin, uncoupler carbonyl cyanide-
4-(trifluoromethoxy) phenylhydrazone (FCCP) and inhibitors antimycin A and rotenone were 
diluted in dimethyl sulfoxide (DMSO) and stored in -20°C.  Inhibitor malonate was prepared by 
dilution in distilled water and stored in -20°C. Saponin for permeabilization of cells was prepared 
always fresh. pH of all reagents was adjusted to 7.4. All media were purchased from Thermo Fisher 






















Figure 10. Overview of study design of all experiments. Note: ETC = Electron transfer chain, FAO 
= Fatty acid oxidation, MTS = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 






15.9.1 Cell viability measurement  
Firstly, we determined cell viability after exposure of cells to different propofol 
concentrations. Cell viability was analyzed by CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Corp., Madison, WI, USA) as previously described166. In literature, 
the assay is known as “MTS viability assay”. It is a colorimetric method, which is routinely used for 
determining the number of viable cells. Assays are performed by adding a small amount of the 
Solution Reagent (containing a tetrazolium compound (MTS; [3-(4,5-dimethylthiazol-2-yl)-5-
(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]) and an electron-coupling 
reagent (PES; phenazine ethosulfate) directly to wells with cells. Cells are then incubated for 1–4 
hours in a humified atmosphere in 5% CO2 incubator at 37°C and, after incubation, absorbance at 
490 nm is measured using spectrophotometer. The quantity of formazan product as measured by 
the amount of 490 nm absorbance is directly proportional to the number of living cells in culture.  
In our experiments, prior to exposure, myoblasts were seeded at density of 1 x 104 cells per well 
on 96-well gelatine-coated microplate. After 24 hours of incubation in “Growth Medium”, the cells 
reached confluence and medium was changed to “Differentiation Medium”. Differentiated 
myotubes were treated for 96 hours with a range of propofol concentrations (1, 2.5, 5, 10, 25 and 
50 µg/mL) diluted in ethanol, Intralipid vehicle (see Figure 11, part A) and mixture of non-
esterified fatty acids at the total concentration of 500 µM (see Figure 11, part B) or the 
combination of propofol either with Intralipid or NEFA. Control cells were incubated either in the 
differentiation medium alone or medium containing 0.01 % ethanol. After exposure, MTS reagent 
with electron coupling agent phenazine methosulfate was added into each well of cells. After 2 
hours of incubation, absorbance was recorded at 490 nm using spectrophotometer (TECAN 
Infinite PRO).  Each experiment was performed in triplicates. This assay helped us to determine 
concentrations suitable for other experiments. Since the highest concentrations (25 and 50 µg/mL) 
of propofol range significantly decreased viability of cells (see Results), we excluded them from 
other experiments.   



























Figure 11. MTS viability assay on 96-well microplate.  Myotubes (10 000 cells/per well) were 
exposed for 96 hours to various conditions. Part A. CON=P0: control = propofol at concentration 
0 µg/mL (= differentiation medium alone); CON=ETH: control = 0.01% ethanol; P1-50: propofol at 
concentrations 1-50 µg/mL; IL10-500: Intralipid at concentrations 10-500 µg/mL; P1-50+IL10-500: 
mixture of propofol and Intralipid at concentrations 1-50 µg/mL and 10-500 µg/mL, resp.; Part B. 
NEFA: non-esterified fatty acids = fatty acid mixture resembling fatty acid composition of Intralipid 
= linoleate: oleate: palmitate in ratio 6:3:1 at the total concentration of 500 µM;  P1-50+NEFA: 
mixture of propofol and non-esterified fatty acids at concentrations 1-50 µg/mL and 500 µM, 





15.9.2 Extracellular Flux Analysis  
Bioenergetic profile of cells was studied using XF-24 Extracellular Flux Analyzer (Seahorse 
Bioscience [Agilent Technologies Inc., Santa Clara, CA, USA]). 
Principle of XF-24 Extracellular Flux Analyzer. The method measures simultaneously the 
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) with oxygen-sensing 
fluorophores and pH sensors. The technology uses a piston to reversibly enclose a small volume 
(7 μl) above the microlayer of cells seeded in a 24-microwell plate (see Figure 12), monitoring 
oxygen uptake in that volume for 2–5 min and then raising the piston167, allowing the bulk 
incubation medium (∼1 ml) to re-equilibrate168,169. The amount of dissolved oxygen and free 
protons in microchamber is measured at baseline of experiment and after addition of up to 4 test 
agents. Any drug or tested compound can be added to cell culture to screen its effect on 
bioenergetics either prior to experiment (e.g. for a model of chronic exposure) or it can be injected 
as one of the 4 agents during the measurement process (rather a model for acute exposure). The 
dynamics of OCR enables to assess energy metabolism. Four wells are usually used as background 
control, with the remaining 20 wells for testing samples (cells or some cellular organelles) at 
different conditions in tri- to tetraplicates. XF-24 Extracellular Flux Analyzer can be used to monitor 
the respiration of cells and organelles that can be attached to the multi-well plate167, either 
spontaneously in the case of cultured cells168 (= attachment on the plastic bottom of wells or 
surface coated by e.g. fibronectin, collagen or gelatine according to specific cell line) or by 
centrifugation of isolated mitochondria169 or synaptosomes170. A novel approach was developed 
for assessment of mitochondrial function in  pancreatic islets171.  
Figure 12. Simplified schema of XF-24 Extracellular Flux Analysis:  
cartridge with 4 ports for 4 compounds, firstly manually pipetted 
into ports, and then injected automatically during measurement 
into well with cell monolayer on 24-well microplate, which is settled 
under cartridge.  
Seeding of cells in a 24-well plate. In our experiments, we used either intact or 
permeabilized cells. For seeding cells and measurement on XF-24 Extracellular Flux Analyzer, we 
used protocol previously described by our group149. In this study in preliminary experiments, we 
determined a suitable number of cells seeded in each well of microplate. We tried to achieve a 
sufficient levels of oxygen consumption rate (reflecting adequate and clear response to injected 
agents) and to avoid a rapid depletion of oxygen concentration at the same time. We tried 
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concentrations between 20 000 and 75 000 cells/per well, as this is usual for most of cell lines. 
According to the results, we chose the number of density for 30 000 cells/per well149. 
Prior to exposure, myoblasts were seeded at the density of 30 x 104 cells per well overnight 
on gelatine-coated 24-well XF-24 V7 cell culture microplates (Seahorse Bioscience [Agilent 
Technologies Inc., Santa Clara, CA, USA]). During the seeding, 30 000 cells were seeded per well in 
volume of 100 µL of “Growth Medium”. After 60 minutes incubation in 5% CO2 atmosphere, cells 
were sufficiently attached to gelatine-coated surface and 150 µl of “Growth Medium” was added 
to each well to get the final volume of 0.25 mL. These steps enabled cells to evenly cover and 
spread on the bottom surface of the well preventing their accumulation in the edge of the well. 
Cells were seeded overnight and reached the confluency of   ̴80-90 %. Next day, “Growth Medium” 
was switched into “Differentiation Medium”. On plate, cells were divided into 6 groups and various 
experimental conditions were formed. 20 wells were used for testing cells at different propofol 
concentrations (0, 1, 2.5, 5 and 10 µg/mL) and controls: fresh medium and either ethanol or 
Intralipid in tri- or tetraplicates (see Figure 13, part A). Each tested group with propofol contained 







Figure 13. Part A. 24-well microplate with cells.  Myotubes (30 000 cells/per well) were exposed 
to various conditions. 4 groups represent myotubes incubated in 4 different propofol 
concentrations (1, 2.5, 5 and 10 µg/mL). Control groups were defined as cells cultivated in fresh 
medium alone without propofol (0 µg/mL). The last tested group was either intralipid vehicle (100 
µg/mL) or 0.01% ethanol. Group of 4 wells on plate  represent background control (=wells 
where cells were not seeded). Part B. “Seahorse” cartridge plate. Each well has 4 ports: A, B, C, 
D. Into each port, a compound (substrate/uncoupler/inhibitor) is pipetted prior to measurement. 
During measurement, compounds are gradually automatically injected in time slots. 
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 Preparation a day before the Experiment. Seahorse cartridge was hydrated with XF 
Calibrant and incubated in humified non-CO2 37°C incubator overnight according to manufacturer 
instructions172. The temperature in XF-24 Extracellular Analyzer was settled down to 37°C and kept 
during the whole experiment. 
Preparation during a day of the Experiment. Cells seeded on 24-well microplate were 
checked under a microscope before measurement. The cells were then carefully rinsed with pre-
warmed DPBS and XF Assay Medium (Seahorse Bioscience [Agilent Technologies Inc., Santa Clara, 
CA, USA]) with 4 mM Glucose, 1 mM pyruvate and 2 mM Glutamine (pH of medium was adjusted 
to 7.4 at temperature of 37°C). After that, 500 µL of XF Assay Medium was pipetted to each well 
and cells were pre-incubated in the incubator without 5% CO2 at temperature 37°C, whilst all the 
substrates, uncouplers and inhibitors were pipetted to “Seahorse” cartridge plate (see Figure 13, 
part B), which was immediately inserted into Extracelular Flux Analyzer. After calibration, 24-well 
microplate with cells was inserted into the machine (below the level of cartridge, see Figure 12) 
and experiment was initiated.   
In our study, we assessed global mitochondrial parameters, respiration linked to individual 
complexes and fatty acid oxidation:  
A. Global mitochondrial functional parameters  
In the first phase of experiment, we evaluated main components of mitochondrial function 
in intact cells (see Figure 14): basal respiration, ATP turnover, proton leak, maximum respiratory 
capacity and non-mitochondrial respiration. 
Basal respiration is the state in initial phase of experiment, when cells have only 
endogenous substrates, which are oxidized and slowly exhausted, but no exogenous substrates or 
ADP is added to stimulate oxygen consumption173. After oxidation of endogenous substrates, only 
non-mitochondrial respiration remains173. Non-mitochondrial respiration is based on activity of 
non-mitochondrial oxygen consuming enzymes. Some cell lines, e.g. macrophages, have highly 
activated non-mitochondrial NADPH oxidases167. Most other cells have low but significant non-
mitochondrial oxygen consumption, around 10% of total, caused by different desaturase and 
detoxification enzymes167. Mitochondrial respiration is assumed to be constant167. Other states 
are usually corrected for non-mitochondrial respiration174.  ATP turnover. Since oxidative 
phosphorylation is linked with respiration, the rate of mitochondrial ATP synthesis is determined 
from the decrease in respiration by inhibiting the ATP synthase with ATPase inhibitor 
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oligomycin167. Proton leak across the mitochondrial membrane can be directly measured after 
enzymatic inhibition of the phosphorylation system167. Leak respiration is generated by flux of 
protons along the electrochemical proton gradient across the inner mitochondrial membrane175 
and represents a dissipative component of respiration which is not available for performing 
biochemical work and thus related to heat production176. A large increase may mean that the 
mitochondria are severely damaged (uncoupled)167. Maximum respiratory capacity is measured 
as oxygen consumption in the noncoupled state at optimum uncoupler concentration177. This 
optimum concentration is obtained by stepwise titration of an established protonophore to induce 
maximum oxygen flux177. Uncoupler effect leads to proton leakage through the inner 
mitochondrial membrane and allows electron transport chain to work in its maximum rate.  
 
In our experiment, basal respiration was measured at the start of measurement (phase 1, 
see Figure 14)149. Subsequently, we used the sequence of 3 added agents to test global 
mitochondrial indices: an ATPase inhibitor oligomycin (phase 2), followed by an inner membrane 
uncoupler, FCCP (carbonyl cyanide-4-[trifluoromethoxy]phenylhydrazone, phase 3). Finally, we 
blocked the respiratory chain complex III with Antimycin A (phase 4). Oxygen consumption after 
exposure to Antimycin A is considered non-mitochondrial (see Figure 14). Basal OCR was 
calculated as OCR Phase 1 – OCR Phase 4. When comparing OCR before and after exposure, the 
absolute cell number is irrelevant since the same population of cells is compared. Therefore, most 
parameters of energy metabolism were expressed as a percentage of baseline value. ATP turnover 
was calculated as 100*(OCR Phase 1 – OCR Phase 2)/Basal OCR [%]. Leak through the inner 
mitochondrial membrane was calculated as 100*(OCR Phase 2 – OCR Phase 4)/Basal OCR [%]. By 
analogy, respiratory chain capacity (or maximum respiration) was calculated as 100*(OCR Phase 3 
– OCR Phase 4)/Basal OCR. From obtained data from the experiment, we determined extracellular 



















Figure 14. The principle of Extracellular Flux Analysis: basic experimental design (“stress test”) 
for assessment of global mitochondrial parameters. FCCP, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone; OCR, oxygen consumption rate; Ox Phos, oxidative 
phosphorylation. Krajčová et al., 2015149.  
Optimizing the XF-24 Extracellular Flux Analysis protocol for human myoblasts. Titration of 
uncouplers and inhibitors. Since it is critical to titrate the ATPase inhibitor and the uncoupler in 
each new cell line and condition167, we firstly had to determine optimum concentrations of these 
agents. We performed our experiment with propofol-exposed cells according to our previous 
study, where we had compared the effects of 0.75, 1, and 1.5 µM oligomycin achieving maximum 
inhibition of ATPase with 1 µM149. This concentration was therefore used for the rest of the 
experiments. Similarly, we had compared uncoupling effects of 0.5, 1, and 2 µM FCCP and 
achieved maximum OCR with 1 µM149. Finally, to verify the ability of 4 µm Antimycin A to inhibit 
the respiratory chain, we had performed an experiment in which we added 0.6 M KCN (complex 
IV inhibitor) after Antimycin A. No additional decrease in OCR was seen with the addition of 
cyanide149. Duration of measurement. We have an experience that prolonged duration on 
Extracellular Flux Analyzer can have a negative impact on some cell lines, as we were able to 
observe their minimal response to oligomycin after long period. We hypothesize that this could 
probably mean that mitochondria in cells are uncoupled after too long period staying inside the 
machine. In this case, it is needed to shorten the time of measurement. In our cell line, we 
determined the safe duration of experiment for 240 minutes. In the pilot study, we checked that 
in control wells (which were left without addition of inhibitors during measurement), OCR 
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remained stable during the whole period. Moreover, oligomycin-induced decrease of OCR (in wells 
with injection of agents) was sufficient.  
Design of protocol on XF-24 Extracellular Flux Analyzer. In this experiment, we did not use 
port D, as we added only 3 agents in ports A, B and C. Baseline OCR was measured in 3 cycles (3 
minutes mixing, 2 minutes waiting and 2 minutes measuring). Then the 3 cycles (3 minutes mixing, 
2 minutes waiting and 3 minutes measuring) were repeated after adding oligomycin (1 µM), FCCP 
(1 µM) and Antimycin A (4 µM).  
B. Respiration linked to individual complexes of electron transfer chain 
Changes in respiration may correlate to altered mitochondrial substrate oxidation. 
Therefore, examining the effect of specific substrates for individual complexes of respiratory chain 
is one approach to determine the mechanism underlying the observed differences178. Since the 
basic measurement in our study showed us changes between mitochondrial function of propofol-
treated cells and control cells (see Results), we continued to test electron transfer system in more 
detail and measured the respiration linked to individual complexes (C I, II, III and IV) of electron 
transport chain. Energy metabolism was studied under both ATP-coupled and uncoupled 
respiration. 
Seeding of cells in 24-well plate. In this experiment studying the function of respiratory 
complexes, we used the same design of cell exposure as in previous one (described above for 
assessment of global mitochondrial parameters; see Figure 13, part A). Similarly, differentiated 
cells were exposed to four different concentrations of propofol (1, 2.5, 5 and 10 µg/mL), control 
groups were defined as cells cultivated in fresh “Differentiation medium” without propofol (0 
µg/mL) and the last tested group was exposed to either Intralipid (100 µg/mL) or 0.01% ethanol. 
Preparation of cells for experiment including permeabilization step. We used the same 
protocol as mentioned above. The differences in protocol design were performed at the day of 
experiment on Extracellular Flux Analyzer. It is needed to add ADP and substrates with high 
molecular weight for testing individual complexes of respiratory chain. These macromolecules 
cannot freely cross cell membranes. Therefore, it is necessary to permeabilize cell membrane. This 
can be achieved by mechanical cell disruption or chemical permeabilization using detergents179. 
Usually, cell lines are in an in vitro studies permeabilized with classical chemical detergents: 
saponin, digitonin or novel agent recombinant perfringolysin O (rPFO; XF PMP reagent; Seahorse 
Bioscience [Agilent Technologies Inc., Santa Clara, CA, USA])178. For our experiments, we used 
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saponin detergent, which interacts with membrane cholesterol, selectively removing it and 
leaving holes in the membrane180. Cholesterol-containing membranes (including cell membrane 
and membranes of endoplasmic reticulum, the Golgi apparatus or lysosomes) are readily 
permeabilised by saponin whilst membranes with lack of cholesterol (inner nuclear membrane 
and mitochondrial membrane) remain intact181. Saponin is a cholesterol-like sugar-containing 
compound produced by several plants, which has a large lipophilic region that inserts into 
membranes and interacts with steroids, phospholipids and proteins, disrupting cholesterol-
phospholipid interactions to create ring-shaped complexes with pores of 12-15 nm diameter, 
which allows the entry of macromolecules181. According to electron microscopy, the rest of plasma 
membrane is relatively intact181. In preliminary experiments, we optimized permeabilization 
protocol for human skeletal muscle cells, because this process is highly dependent on reagent 
concentration, exposure time and temperature and can differ in each cell line. Saponin 
concentration must be sufficient to enable macromolecules entry across the membrane inside the 
cell, but it should not be too high because of risk of mitochondrial and cell damage.  Damage of 
mitochondria by saponin is usually evident only at concentrations of >25 μg/mL saponin182. For 
our experiments on human myotubes, we observed that concentration of 5 µg/mL saponin with 
4-5 minutes of incubation was effective and safe.  
Preparation during a day of Experiment. All media and solutions were prepared fresh 
shortly before experiment. For measurement with permeabilized muscle cells, we used 
Mitochondrial Assay Solution (MAS) instead of XF Assay Medium according to the manufacturer 
recommendations183. MAS is a non-ionic mannitol and sucrose-based buffer used in 
permeabilization assays183. Our solution consisted of 220 mM mannitol, 70 mM sucrose, 10 mM 
KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM bovine serum albumin (BSA), EGTA, 0.2% BSA and 
distilled water. BSA was included into the MAS buffer, because it is essential for maintaining well-
coupled mitochondria following permeabilization182. We made sure that all BSA was properly 
dissolved, then warmed MAS to 37°C and adjusted pH to 7.4. To avoid a prolonged exposure and 
contact of cells to MAS which could be harmful for cells184, we needed to shorten the length of 
both preparation and measurement as much as possible. In addition, shortened measurement 
helped us to prevent rapid burst of ADP. Therefore, we pipetted all substrates and inhibitors into 
4 ports of seahorse cartridge, inserted the cartridge into the machine and initiated calibration. 
Whilst the process of calibration (  ̴25 minutes) was running, we were preparing plate with cells. 
Firstly, we gently aspirated the old “Differentiation Medium”, washed cells with pre-warmed MAS 
alone and incubated them in MAS with 5 µg/mL saponin for 4-5 minutes in air at room 
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temperature. During the process we were careful not to touch the plate. After that, we  carefully 
discarded the medium with saponin and added pre-warmed MAS supplemented with 4 mM ADP 
and substrates for complex I: 2.5 mM malate and 15 mM glutamate (pH of MAS supplemented 
with substrates was again checked and adjusted to 7.4).  Immediately after the change of medium 
and pipetting MAS, plate was inserted to calibrated XF-24 Extracellular Flux Analyzer. The whole 
process of cell preparation for measurement did not take more than 20-25 minutes.  
Mitochondrial indices obtained during measurement on permeabilized cells. In our first 
experiments, we analysed main mitochondrial functions on experimentally uncoupled respiration 
in intact cells. FCCP and inhibitors can freely cross the cell membrane and get into mitochondria 
in comparison with macromolecules as ADP or substrates. In permeabilised cells, we used both 
uncoupled and coupled respiration.  
During oxidative phosphorylation (OXPHOS), metabolites are oxidized donating reducing 
equivalents to coenzymes nicotinamide adenine dinucleotide (NAD+) and flavin adenine 
dinucleotide (FAD) to generate NADH+H2 and FADH2185. After that, electrons enter the electron 
transport chain complexes in the mitochondrial inner membrane and pass down a decreasing 
energy potential gradient. The resulting energy release drives proton pumping across the inner 
mitochondrial membrane from the matrix to the intermembrane space by complexes I, III, and 
IV185. The electrochemical gradient, or proton motive force (Δp), that is established by proton 
pumping, then drives protons back into the mitochondrial matrix through the ATP synthase to 
generate ATP. Finally, electrons are transferred to complex IV, cytochrome c oxidase, and then 
donated to molecular oxygen leading to H2O production185. In summary, oxidative 
phosphorylation is the oxidation of reduced fuel substrates by electron transfer to oxygen which 
is chemiosmotically coupled to the phosphorylation of ADP to ATP186.  
Uncoupling of oxidative phosphorylation means a loss of coupling between the rate of 
electron transport in the respiratory chain (respiration) and ATP production (phosphorylation) 
without affecting respiratory chain187. Uncoupled respiration, experimentally induced by addition 
of protonophore (e.g. FCCP), is a maximum electron flow in mitochondria without ATP formation 
and reflects the capacity of mitochondria to response to increased demand.  
Respiratory states. In the first part, we simply described testing of the global mitochondrial 
parameters: basal respiration, proton leak, ATP production and maximum respiratory capacity. 
According to the classical work of Chance and Williams from 1955188, we can describe the different 
conditions during experiment as several „respiratory states” for assessment of mitochondrial 
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functions. This can be useful particularly when assessing ADP-stimulated respiration. Oxygen 
consumption is measured at baseline in the presence of only inorganic phosphate (Pi) (= State 
1)173,182. Substrates such as glutamate plus malate or succinate are then added to measure ADP-
independent respiratory activity (= State 2)182. Addition of ADP is  signed as State 3 respiration, 
which is defined as the ADP -stimulated respiration in the presence of high ADP and Pi 
concentrations supported by a defined substrate or substrate combination at saturating oxygen 
levels. In this phase, addition of ADP leads to fast oxygen consumption rate and the formation of 
ATP. When ADP is depleted, respiration returns to rates similar to that of State 2 (= State 4)182. 
State 4 respiration is also induced by addition of ATPase inhibitor oligomycin182 and represents 
LEAK respiration. An uncoupler may be added to mitochondria in State 4 or in the absence of ADP 
(but in the presence of oxygen and fuel substrates), which leads to an increase of respiration to a 
rate equal to that in State 3 or higher. This state is used as State 3u (uncoupled) and represents 
noncoupled state of electron transfer capacity189.  
Design of the first experiment: CI, II and IV-linked respiration (see Figure 15). Cells were 
incubated in medium with 4 mM ADP and substrates for complex I (2.5 mM malate and 15 mM 
glutamate). OCR was immediately measured at baseline. During the experiment, we continued 
with injection of complex I-linked inhibitor (3 µM rotenone) followed by the substrate for complex 
II (10 mM succinate). After that, respiration was blocked with complex II-linked inhibitor (5 mM 
malonate). Finally, we added 10 mM ascorbate with 0.2 mM TMPD (N,N,N',N'-tetramethyl-p-
phenylenediamine) to assess complex IV-linked respiration.  
Design of the second experiment: CIII-linked respiration (see Figure 16). 15 mM glutamate, 
2.5 mM malate and 10 mM succinate were added to the permeabilized cells prior to the start of 
assay. During the measurement, cells were initially uncoupled by FCCP and respiration was 
subsequently inhibited by complex I and II-linked inhibitors (3 µM rotenone plus 5 mM malonate). 
Complex III-linked respiration was measured as oxygen consumption rate after addition of 0.6 mM 
duroquinol, which was prepared from its oxidized form duroquinone (Sigma-Aldrich, Corp., St. 
Louis, MO, USA) as previously described165. In the last step, respiration was blocked by 4 µM 
Antimycin A.  
Design of the third experiment: Correlation between the capacity of any of the respiratory 
complexes and ETC spare capacity. We measured respiration linked to individual complexes and 
global mitochondrial parameters (see Figure 14) in parallel from the same subject to determine a 













Figure 15. Extracellular Flux Analysis: measurement of complex I-, complex II- and complex IV-
linked respiration (coupled respiration). Cells were incubated in medium supplemented with 
glutamate + malate as substrates for complex I and ADP. Reagents injected during the experiment: 
rotenone was used as complex I inhibitor, succinate as substrate for complex II, malonate as 
complex II inhibitor and, finally, ascorbate (Asc) with TMPD (N,N,N′,N′-tetramethyl-p-









Figure 16. Extracellular Flux Analysis: measurement of complex III-linked respiration (uncoupled 
respiration). Cells were incubated in medium supplemented with glutamate + malate + succinate 
(substrates for complexes I and II). Reagents injected during the experiment: cells were uncoupled 
by addition of FCCP ([carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone]; uncoupled 
complex I and II respiration) and subsequently malonate + rotenone were added as inhibitors. 
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Then, duroquinol was injected as substrate for complex III. Finally, Antimycin A as complex III 
inhibitor was added. 
Duration of measurement on Extracellular Flux Analyzer. As we previously mentioned, we 
tried to maximally shorten period of measurement to avoid prolong incubation of cells in MAS 
medium and, in case of coupled respiration, to prevent rapid exhausting of ADP. Baseline OCR was 
measured in 3 cycles (0.5 minute mixing, 0.5 minute waiting and 2 minutes measuring). Then the 
3 cycles (0.5 minute mixing, 0.5 minute waiting and 2 minutes measuring) were repeated after 
injection of agents in ports A, B, C and D.  The length of experiment was not longer than 70 minutes 
(including calibration and equilibration of cartridge plate and plate with cells resp.). 
C. Fatty acid oxidation 
It was hypothesized that propofol could have an impact on fatty acid oxidation68,116.  In our 
experiment, we wanted to test possible impact of long-term incubation of both 2,6-
diisopropylphenol and its vehicle in propofol infusion on skeletal muscle cell mitochondria. We 
tried to reflect the fact that after administration of intralipid infusion, it is in vivo hydrolysed 
releasing free fatty acids in human plasma160,161. Therefore, to investigate fatty acid metabolism 
we slightly modified a design of cells exposure to propofol before measurement on XF-24 
Extracellular Flux Analyzer. 
Seeding of cells and exposure to experimental conditions in 24-well plate before 
measurement.  Prior to exposure, cells were cultivated as usual and differentiated to form 
myotubes for 7 days. After that, cells started to be exposed to various conditions for 96 hours. 
Two groups were exposed to propofol alone (2.5 and 10 µg/mL; see Figure 17). Another groups of 
cells were exposed to medium containing same concentrations of propofol (2.5 and 10 µg/mL) 
combined with NEFA, which were prepared to resemble fatty acid composition of Intralipid (with 
the ratio of fatty acids: 55% of linoleic acid, 27% of oleic acid and 10.5% of palmitic acid)162 at the 
total concentration of 500 µM. Control groups of cells were cultured either in fresh 
















Figure 17. 24-well microplate with cells for FAO experiment.  Myotubes (30 000 cells/per well) 
were exposed to various conditions. 2 groups represent myotubes incubated in 2 different 
propofol concentrations (2.5 and 10 µg/mL). Control groups were defined as cells cultivated in 
fresh “Differentiation medium” without propofol (0 µg/mL) or cells incubated in non-esterified 
fatty acids (NEFA) mixture (with the ratio of fatty acids: 55% of linoleic acid, 27% of oleic acid and 
10.5% of palmitic acid). Last 2 groups were exposed to both propofol (2.5 and 10 µg/mL) and NEFA 
mixture.  
Aim of this experiment was to test mitochondrial response to addition of fatty acids as 
substrates (by injection of sodium palmitate on Extracellular Flux Analyzer). We used palmitate as 
a standard long-chain fatty acid which enabled us to test whole pathway including both enzymes 
that are involved in fatty acid transport into mitochondria and enzymes that ensure fatty acid 
metabolism itself (see Figure 27 in Discussion).  We wanted to look at the differences in individual 
groups of cells and to compare myotubes exposed to 2,6-diisopropylphenol alone and myotubes 
incubated in propofol with propofol with NEFA mixture.  
Fatty acid oxidation and carnitine transport. Long-chain fatty acids are transported 
through plasma membrane by fatty acid transporter CD36 and then activated by esterification to 
CoA-SH, which is catalysed by acyl-CoA synthetases190. For transport into mitochondria fatty acyl-
CoA molecules need to be transported by carnitine through action of carnitine 
palmitoyltransferase-I (CPT-I). A carnitine/acyl-carnitine translocase (CACT) then shuttles acyl-
carnitines into mitochondria, where carnitine palmitoyltransferase-II (CPT II) regenerates the acyl-
CoA molecule which is then oxidized in process of fatty acid oxidation (β-oxidation)190. This 
multiple reaction process results in production of Acetyl-CoA, which serves as fuel for TCA cycle. 
In addition,  the process generates also reducing equivalents FADH2 and NADH+H+, which are then 
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passed to Coenzyme Q, through electron transfer flavoprotein (ETF) dehydrogenase and to 
complex I, respectively190.  
For experiment, we therefore used non-permeabilised intact cells incubated in respiration 
medium supplemented with 0.5 mM carnitine. 
Preparation during a day of Experiment. Prior to the experiment, we prepared KHB 
medium containing 111 mM NaCl, 4.7 mM KCl, 2 mM MgSO4, 1.2 mM Na2HPO4 and distilled water 
according to manufacturer recommendations191. 2.5 mM Glucose and 0.5 mM carnitine were 
prepared fresh and added to KHB medium. The solution was pre-warmed to 37°C and pH was 
adjusted to pH 7.4. Cells were firstly checked under microscope and old medium was carefully 
discarded. After that, they were washed with pre-warmed KHB medium and then KHB was added 
to the cells. Plate with cells was inserted to humified non-CO2 incubator for 50-60 minutes. Whilst 
cells were incubated, the seahorse cartridge was prepared as usual and 4 agents were pipetted to 
ports A, B, C and D. Preparation of sodium palmitate. Sodium palmitate was used as a substrate 
for fatty acid utilization and prepared as previously described192. Bovine Serum Albumin (BSA) was 
used as a carrier for insoluble palmitate, because palmitate conjugation to BSA creates an 
aqueous-soluble reagent that can be easily absorbed and utilized by cells. 1 mM sodium palmitate 
was prepared in 150 mM NaCl and 0.17 mM BSA in 150 mM NaCl. Sodium palmitate solution was 
heated to 70°C on a heated stir plate until its colour became clear, and then an equal volume of 
hot sodium palmitate was added to the BSA solution (the molar ratio between palmitate and BSA 
was 6:1). After that, the solution was stirred at 37°C for 1 hour and the pH was adjusted to 7.4. 
The stock of sodium palmitate was stored in -20°C for up to maximum of 2 months. 
 Design of protocol on Extracellular Flux Analyzer (see Figure 18). Firstly, intact myotubes 
were uncoupled by injection of 1 µM FCCP (port A) to achieve maximum respiration rate. Fatty 
acid oxidation was then measured as etomoxir-induced inhibition of oxygen consumption rate 
after repeatable addition of sodium palmitate (at the total concentration of 200 µM; ports B and 
C). 40 µM etomoxir was injected after that (port D).  Baseline OCR was measured in 3 cycles (0.5 
minute mixing, 0.5 minute waiting and 2 minutes measuring). Then the 3 cycles (2 minutes mixing, 

















Figure 18. Extracellular Flux Analysis: measurement of fatty acid oxidation. Intact cells were 
incubated in KHB medium supplemented with 0.5 mM carnitine. Firstly, cells were uncoupled with 
FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone). After that, sodium palmitate was 
repeatedly added as a substrate for FAO (at the total concentration of 200 µM). Fatty acid 


















15.9.3 Protein content and Citrate synthase activity 
After each experiment performed on XF-24 Extracellular Flux Analyzer, cells were checked 
under microscope. The respiration medium was carefully discarded, and cells were washed with 
pre-cold PBS. Cell buffer lysis (150 µL/well) and protease inhibitor cocktail (2 µL/well) were added 
into each well with cells and plates were stored immediately at – 80°C for further analysis of 
Citrate synthase (CS) activity and protein content. 
Citrate synthase is the initial enzyme of TCA cycle, which catalyses the reaction between 
acetyl-CoA and oxaloacetic acid to form citric acid. Citrate synthase is widely used as a marker of 
the mitochondrial density165,193. CS activity was analysed using CS Assay kit (Sigma-Aldrich, Corp., 
St. Louis, MO, USA) and measured according to manufacturer’s instructions194. Briefly, we 
prepared all the solutions as recommended before this assay (Assay buffer with 200 mM Tris with 
0.2% Triton, adjusted to pH 8; 10 mM 5,5′-Dithiobis-(2-nitrobenzoic acid) [DTNB]; 30 mM Acetyl-
CoA and 10mM Oxaloacetate [OAA], prepared fresh at the day of assay). The 24-well plate was 
gradually thawed slowly shaking on ice, samples from the bottom were thoroughly harvested and 
transferred to small Eppendorf tubes and centrifuged for 10 000 xg, for 10 minutes at 4°C. After 
that, 100 µL of supernatant from each sample in Eppendorf tube was mixed with 86 µL of Assay 
buffer with addition of 2 µL of 10 mM DTNB and 2 µL of 30 mM Acetyl-CoA. Spectrophotometric 
Assay was then initiated by measuring absorbance at 412 nm to obtain baseline194. For 
spectrophotometry TECAN Infinite M200 Pro microplate reader was used. Subsequently, we 
added 10 µL of 10 mM OAA solution to each well at the same moment using multichannel pipette 
to initiate the reaction and measurement of absorbance at 412 nm was then repeated. The 
principle of reaction could be described as followed: hydrolysis of the thioester of acetyl-CoA 
resulted in the formation of CoA with a thiol group (CoA-SH)194. The thiol reacted with the DTNB 
in the reaction mixture to form 5-thio-2-nitrobenzoic acid (TNB)194. This yellow product (TNB) was 
then observed spectrophotometrically by measuring absorbance at 412 nm194. 
Reaction catalysed by Citrate synthase: Acetyl CoA + OAA → Citrate + CoA-SH + H+ + H2O  
Colorimetric reaction: CoA-SH + DTNB → TNB + CoA-S-S-TNB 






15.9.4 Analysis of acid soluble metabolites 
In 2016, we started to cooperate on this project with research team of professor Arild 
Rustan (School of Pharmacy, University of Oslo, Norway) as he offered us to perform analysis of 
acid soluble metabolites which is not possible to do at our faculty. We sent our Norwegian 
colleagues the frozen cell cultures, which had been previously used for our experiments and then 
stored in liquid nitrogen. Unfortunately, these cells could not be used for other techniques 
because of transport difficulties. After arrival to Norway, cells were not viable. Therefore, our 
Norwegian colleagues had to use skeletal muscle cells obtained from vastus lateralis biopsies from 
healthy volunteers in Norway (n = 5). The biopsy technique, which they used, was performed by 
Bergström needle145. All conditions including isolation, cultivation, differentiation and exposure of 
cells to propofol, were the same as ours. After 4 days of propofol treatment, the medium was 
completely removed before addition of 0.5 µCi/mL [1-14C] palmitic acid (PerkinElmer NEN®, 
Boston, MA, USA), given in DMEM-GlutamaxTM (low glucose, 5 mmol/L) with L-carnitine (1 
mmol/L) and BSA (40 µmol/L). The cells were incubated at 37ᵒC for 4 hours before the incubation 
media were collected. Oxidation of [1-14C] palmitic acid to acid-soluble metabolites (ASMs) was 
measured by acid precipitation of the incubation media. ASMs reflect incomplete fatty acid 
oxidation in the mitochondria and consist mainly of tricarboxylic acid cycle metabolites. In brief, 
100 µL of the incubation media were added 30 µL BSA (6%) and 300 µL HClO4 (1 mol/L) and 
centrifuged at 10.000 rpm / 4ᵒC / 10 min. Then 200 µL of the supernatant was counted by liquid 
scintillation (Packard Tri-Carb 1900 TR).  
 
15.9.5 Spectrophotometric analysis of individual activities of respiratory complexes 
and octanoyl-dehydrogenase activity 
After 96-hours incubation in various conditions (medium with propofol concentration of 
2.5 and 10 µg/mL vs. “Differentiation medium” [=0 µg/mL propofol] for control group), myotubes 
were washed by phosphate buffer saline, harvested from Petri dishes using cell scraper (Biologix) 
and then centrifuged at 350 xg for 10 minutes at room temperature. The supernatant was 
discarded, and the pellet was frozen and stored in -80 °C for further spectrophotometric analysis. 
When all samples were collected, the frozen pellets were thawed in the “Homogenisation 
Medium” (10 mM Tris-Cl, 10 mM KCl, 150 µM MgCl2, 250 mM sucrose, pH 6.5) and mechanically 
disrupted with a 2 mL glass tight-fitting Dounce homogenizer (Wheaton type B). The homogenate 
was then exposed to 3 further cycles of rapid freezing thawing. The homogenate was then 
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centrifuged at 500 xg at 4 °C and the supernatant was taken for assays. The activities of enzymes 
were assayed spectrophotometrically using TECAN Infinite M200 Pro microplate reader. Complex 
I, II, III and IV activities were performed as described in detail elsewhere196. In brief, frozen samples 
were thawed and homogenized and then exposed to 3 further cycles of rapid freezing thawing. 
Complex I assay was performed in the assay mixture consisting of 25 mM potassium phosphate, 
3.5 g/L BSA, 2 mM ethylenediaminetetraacetic acid (EDTA), 60 μM DCIP, 70 μM decylubiquinone, 
1 μM Antimycin A and 0.2 mM reduced nicotinamide adenine dinucleotide (NADH), pH 7.8196. 
Changes in absorbance were followed at 600 nm. Rotenone sensitive activity was calculated by 
subtracting the activity of wells with 10 μM rotenone. Complex II activity was measured in the 
assay mixture composed of 80 mM potassium phosphate, 1 g/l BSA, 100 mM EDTA, 10 mM 
succinate, 80 μM dichlorophenollindophenol (DCIP), 50 μM decylubiquinone, 1 μM Antimycin A 
and 3μM rotenone, pH 7.8196. Changes in absorbance were followed at 600 nm. Malonate sensitive 
activity was calculated by subtracting the activity of wells with 20 mM malonate. Complex III 
activity was measured in the assay mixture containing 50 μM ferricytochrome c, 25 mM potassium 
phosphate, 4 mM sodium azide, 0.1 mM EDTA, 0.025% Tween 20 and 50 μM decylubiquinol, pH 
7.4196. Changes in absorbance were followed at 550 nm. Antimycin A sensitive activity was 
calculated by subtracting the activity of wells with 10 μM antimycin A. Complex IV activity was 
measured in the assay buffer containing 30 mM potassium phosphate and 25μM of freshly 
prepared ferrocytochrome c, pH 7.4196. Changes in absorbance were followed at 550 nm. The 
absorbance of samples oxidized with 10 μl of 0.5 M potassium hexacyanoferrate (III) was 
subtracted from all measurements, and then the natural logarithm absorbance was plotted 
against time and compared to untreated control. Acyl-CoA dehydrogenase activity was measured 
by modifying the protocol Ijlst and Wanders197. We followed the reduction of 2,6-
dichloroindophenol (DCIP) at 600 nm instead of ferricenium hexafluorophosphate. The assay 
mixture contained 20 mM Tris-Cl (pH adjusted to 8.0), 0.1 % Triton X-100 and 10 mM DCIP and 10 
µL of homogenate. A600 was followed at 37°C with 30 seconds interval until the signal was stable, 









For statistical analysis, we used software Stata 14.2 (Stata Corp., LLC, College Station, TX). 
In order to deal with hierarchical structure of the data, we used a four-level mixed effect model of 
linear regression147. In the fixed part, the model consists of a dependent continuous variable (e.g., 
a bioenergetic variable) and an independent variable, which is a categorical variable describing 
the experimental condition (e.g., the concentration of propofol)147. In the random part, the model 
reflects the following four levels: subjects, experimental condition, well, and repeated measures 
in each well147. The data are presented as the difference (with a 95% CI and p value) between the 
mean value of the dependent variable of reference cells and the mean value of the dependent 




16.1 Cell viability and effect of propofol on mitochondrial and protein  
content 
Cell viability test (MTS test) was the first method that we used to observe propofol effect 
on human skeletal muscle cells. 96 hours exposure of myotubes to propofol up to 10 µg/mL did 
not cause detectable changes in cell survival measured by cell viability test, but higher 
concentrations (25 and 50 µg/mL) were highly toxic (see Figure 19)147. Therefore, we excluded 
them from other experiments. Neither NEFA nor Intralipid alone affected cell survival147. On the 
contrary, when cells were exposed to combination of propofol with either Intralipid or NEFA, it 
seemed that these compounds had protective effect, as viability of cells was higher in comparison 
with groups exposed to propofol alone. In all experiments, exposure to propofol caused a degree 
of dose-dependent reduction of both protein and mitochondrial contents (measured as Bradford 
assay or Citrate synthase activity, respectively; see Figure 20)147. These changes were mirrored in 
changes of basal OCR. Thus, we normalized all functional mitochondrial parameters derived from 





















Figure 19. Results of MTS test. The absorbance on y-axis (arbitrary units) is directly proportional 
to number of viable cells. Protective effects of Intralipid and NEFA (500 µM) are apparent. Krajčová 








Figure 20. Relation between basal oxygen consumption rate (OCR) and Citrate Synthase (CS) 
activity (on the left) and between basal OCR and Bradford protein (BP) content (on the right). 





16.2 Global mitochondrial functional parameters 
Basal oxygen consumption rate was only affected by the highest tested concentration: 10 
µg/mL propofol (see Figure 21, part A)147. Proton leak through the inner mitochondrial membrane 
tended to be increased in a non-concentration dependent manner (from 21% of basal OCR in 
controls to 24–40% in cells exposed to propofol), but this effect only reached statistical 
significance with 2.5 µg/mL of propofol (see Figure 21, part B)147. Spare ETC capacity in control 
cells was 378% ± 135% of basal OCR. It was significantly reduced across all propofol concentrations 
(to 113% ± 96%, 111% ± 77%, 245% ± 155%, 245% ± 188% for 1.0, 2.5, 5.0, and 10 µg/mL of 
propofol, respectively, p < 0.01 for all differences) (see Figure 21, part C)147. No effect was 
observed after incubation of cells in the Intralipid vehicle. Anaerobic glycolysis (as measured as 












Figure 21. Global mitochondrial parameters. Differences in bioenergetic variables (y-axis) caused 
by a range of propofol concentrations (x-axis) diluted in 0.01% ethanol (propofol = 0 refers to 
ethanol alone) compared with reference cells cultured in “Differentiation medium” alone (mean 
from n = 6; vertical bars represent 95% CIs). A, Basal oxygen consumption rate (OCR). B, Leak/ 
basal OCR ratio. C, Electron transfer chain capacity (ETC)/basal OCR ratio. D, The Extracellular 
Acidification Rate (ECAR) reflects the rate of anaerobic glycolysis. Krajčová et al., 2017147.  
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16.3 Fatty Acid Oxidation: Extracellular Flux Analysis and Analysis of  
Oxidation of [1-14C] palmitic acid to acid-soluble metabolites 
By Extracellular Flux Analysis, we found a profound inhibition of FAO which decreased to 
36% and 33% of values in control cells with 2.5 or 10 µg/mL of propofol, respectively (p < 0.01 for 
both; see Figure 22, part A)147. In Experiment with assessment of oxidation of [1-14C] palmitate 
acid  to acid-soluble metabolites, we observed a significant decrease of FAO with 2.5, 5, and 10 










Figure 22. Effect of propofol on fatty acid oxidation. Changes in fatty acid oxidation rate caused 
by propofol measured by Extracellular Flux Analysis (A) and by [1-14C] palmitate technique (B). 
Data expressed as mean % of value in reference cells (i.e., cultured without propofol), which are 
arbitrarily set as 100%. Vertical bars are 95% CI. Krajčová et al., 2017147.  
 
16.4 Respiration linked to individual complexes of electron transfer chain:  
Extracellular Flux Analysis and Spectrophotometric Assay 
When measured isolated activities of individual complexes (Spectrophotometric Assay), 
we have not found any inhibition by propofol of the capacity of respiratory complexes II–IV nor 
ACAD (see Table 2)147. In intact mitochondria of saponin-permeabilized myotubes (Extracellular 
Flux Analysis), there was no effect of propofol 2.5 µg/ mL on ETC complexes either, but with 10 
µg/mL, there was a reduction of the activity of the complexes III and IV (see Table 2 and Figure 
23)147. We observed no correlation between the activity of any of these complexes and ETC spare 









Table 2.  Activity of individual complexes of electron transfer chain analysed using 
Spectrophotometric assay. Mean activities (95% CIs) of individual mitochondrial enzymes 
expressed as % of values in control cells cultured in the absence of propofol. N/A = not applicable. 











Figure 23. Effect of the range of propofol concentrations on respiration linked to individual 






In addition, we looked specifically at complex III-linked respiration and transfer of 
electrons from complexes I and II to complex III by Coenzyme Q (see Figure 27 in Discussion). To 
assess its function, we looked at the results of experiment where cells were in respiration medium 
supplemented with substrates for complexes I and II (malate+glutamate and succinate, resp.) prior 
to measurement on XF-24 Extracellular Flux Analyzer (see Figure 16 in Methods).  After that, 
agents were sequentially added as follows: uncoupler FCCP to maximally stimulate respiration, 
followed by inhibitors of complexes I and II (rotenone and malonate, resp.). Subsequently, 
complex III substrate (duroquinol) was added and respiration was inhibited by inhibitor for 
complex III (Antimycin A). From the measured values, we obtained data reflecting the differences 
between pathway from complex I and II to complex III (= electrons are transferred using Coenzyme 
Q) and pathway where electrons were sent directly to complex III (by addition of duroquinol) 
bypassing Coenzyme Q. We calculated the difference as: OCR after FCCP – OCR after duroquinol. 
OCR after Antimycin A reflecting non-mitochondrial respiration was subtracted from the values. 
According to the results, it seemed that low concentrations of propofol (1 and 2.5 µg/mL) inhibited 
respiration linked to complex I+II (see Figure 24). At higher concentrations there was a trend of 












Figure 24. Effect of the range of propofol concentrations on respiration linked to complex I+II 
and respiration linked to complex III of electron transfer chain analysed by XF-24 Extracellular 





16.5 Influence of NEFA on propofol-induced changes in mitochondrial 
metabolism  
Cells were exposed to propofol (2.5 and 10 μg/mL) with and without NEFA for 96 hours to 
test their possible effect on propofol induced-changes of mitochondrial metabolism. Addition of 
NEFA alone to the media did not affect cell survival (see Figure 19) or global mitochondrial 
functional indices, but it mitigated the inhibitory effects of propofol on basal OCR (see Figure 25, 









Figure 25. Impact of NEFA on propofol-induced changes in mitochondria. Interaction of propofol 
diluted in 0.01% ethanol with increased non-esterified fatty acids (NEFA) in culture media. 
Reference cells were cultured in the fresh “Differentiation medium” alone (propofol = 0 are cells 
cultured in 0.01% ethanol). (A) Changes in basal oxygen consumption rate (OCR). (B) Changes in 
spare capacity of electron transfer chain ratio to basal OCR. ETC = electron transfer chain capacity. 












Firstly, we looked at all 153 PRIS case reports and case series published between 1990 and 
201481. Our analysis of reported cases shows that PRIS has changed over the last 24 years81: a 
typical patient who died with PRIS in the early 1990s was a child with respiratory infection who 
developed PRIS after having received an excessive dose of propofol32,33. Nowadays, PRIS is more 
likely to be seen in an adult or elderly patient sedated by a usual dose of propofol in an ICU in 
whom mild unexplained acidosis and elevation of creatine kinase is noted81, sometimes with 
worsening of acute kidney injury and arrhythmia, but other features of PRIS are often 
missing82,83,85. This can be a consequence of changes of prescription habits, with more ICU patients 
exposed to propofol, but a smaller proportion of them exposed to dangerously high doses81.  
We looked also at the factors associated with higher mortality. Our multivariate analysis 
showed that there are only a few independent predictors of death81. The most important of these 
seemed to be the cumulative dose of propofol, being represented by both mean infusion rate and 
the duration of infusion81. Out of all the other features of PRIS, which seem to increase the 
probability of death in univariate analysis, only the presence of trauma brain injury and fever were 
significantly related to PRIS mortality81.  
We also looked at the dependency of the frequency of PRIS signs on the rate and duration 
of propofol infusion and we observed that dose-related signs of PRIS occurred more frequently 
with higher infusion rates, irrespective of the duration of infusion, and included: cardiac failure, 
metabolic acidosis, fever, and perhaps hypotension81. Signs of PRIS dependent on duration of 
infusion occurred more frequently with longer propofol infusions  (mostly ˃48 hours) irrespective 
of dose and included arrhythmia and other ECG changes81. Rhabdomyolysis and 
hypertriglyceridemia occurred most frequently with high doses of propofol after 96 hours of 
administration and seemed to be dependent on cumulative dose rise in frequency with both the 
dose and time of administration81.  
 However, in some of reported cases, mild unexplained acidosis was even the only sign of 
possible PRIS development, which completely disappeared after propofol withdrawal74. A current 
view on PRIS is therefore quite different from previous Bray’s definition in 90’s. Because symptoms 
can occur in any combination and order and can range from the very mild to severe in each 
individual patient, it is very difficult to determine a precise definition of PRIS81.  
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Our finding that cardiac failure and metabolic acidosis occurred early  and in a dose-
dependent manner is consistent with a direct inhibition of aerobic phosphorylation observed in 
experimental studies81. The heart muscle is highly reliant on aerobic ATP production198 and 
acidosis may represent a combination of hypoperfusion and cytopathic hypoxia in tissues81. Fever 
was reported more frequently with higher propofol infusion doses that might reflect 
mitochondrial uncoupling from ATP production and energy dissipation as heat81. On the contrary, 
arrhythmia and ECG changes occurred more frequently in PRIS cases caused by prolonged 
propofol infusions which could be explained by the fact that arrhythmia and ECG changes are 
caused by elevated free fatty acids, which steadily increase over days during propofol 
administration68 and are known to be proarrhythmogenic199 (even more so in combination with 
metabolic acidosis)81. Similarly, rhabdomyolysis (a common feature of inborn defects of fatty acid 
oxidation200,201) was associated with the duration of propofol administration and might also be 
related to the propofol-induced defect of fatty acid oxidation81. The frequency of 
hypertriglyceridemia seemed to also increase with cumulative dose of propofol81. If the dose of 
lipid emulsions exceeds the capacity of hydrolysis in plasma, triacylglyceroles accumulate in the 
blood and are taken up by the reticulo-endothelial system, causing hepatosplenomegaly, jaundice, 
and clotting disturbances (“fat overload syndrome”202). Recommended lipid dose for parenteral 
nutrition is 29–54 mg/kg per hour203. To match this dose, propofol as a 1 % solution in 10 % 
intralipid has to run at 2.9–5.4 mg/kg per hour. Most of the patients with PRIS exceeded this rate81. 
Nonetheless, it seems that excessive doses of lipid emulsions are generally well tolerated; rapid 
infusions of lipid emulsions even in a range of 170–5000 mg/kg per hour have been accidentally 
administered without side effects204. In animal models of PRIS137,205, elevated triglycerides was the 
only sign observed in control animals receiving intralipid alone.  
In conclusion, the main limitation of our meta-analysis is the risk of publication bias, i.e. 
that the published cases are not representative of the population of patients with PRIS. In 
summary, we found out that cardiac failure and metabolic acidosis occur early in a dose-
dependent manner and could be caused by inhibiting aerobic phosphorylation and fever by 
mitochondrial uncoupling while arrhythmia, other ECG changes and rhabdomyolysis appear more 
frequently after prolonged propofol infusions, irrespective of dose81. In addition, in our meta-
analysis of 153 published PRIS case reports we found that some signs (e.g. rhabdomyolysis) occurrs 
more frequently after propofol infusion longer than 96 hours. This finding helped us to design our 
further experimental in vitro study when selecting the length of propofol exposure: we chose the 
duration of 4 days (= approximately 96 hours) for incubation of cells in propofol.  
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In 90’s, soon after the first case of PRIS, the pathogenesis of syndrome started to be 
extensively studied. First in vitro studies were performed on animals, mostly by exposing isolated 
mitochondria from rat liver128,130,132 or heart129 to very high doses of propofol for a very short time 
(at the range of minutes).  According to them, propofol was thought to act as an inhibitor of 
electron transport chain128–131 and a mild uncoupler of the inner mitochondrial membrane130,132. 
The main limitation of these studies was the short action of propofol on mitochondria at 
concentrations which mostly several times exceeded propofol levels found in vivo in human 
plasma (up to 10 µg/mL) during anaesthesia139 or sedation140,141.  
The only study of long-term in vivo exposure to propofol was published in 2015 by 
Vanlander et al.133 In the study, authors discussed a structural similarity of propofol and Coenzyme 
Q (CoQ) molecule133. They observed eight rats, who were sedated for up to 20 hours with gradually 
increasing doses of propofol (from 20 to 80 mg/per kg/hour) in comparison with group of control 
rats. Liver, skeletal and heart muscle biopsies were performed in different time intervals after 
initiation of propofol administration (after 6; 12; 3.5-8 hours). Tissue samples were homogenized 
to prepare homogenates suitable for spectrophotometric analyses133. The activities of respiratory 
chain complexes (nicotinamide: adenine dinucleotide: coenzyme Q reductase [complex I], 
succinate coenzyme Q reductase [complex II], succinate cytochrome c reductase [complex II+III 
activity], cytochrome c ubiquinol reductase [complex III], cytochrome c oxidase [complex IV]) were 
then measured. The analysis demonstrated that the enzyme succinate cytochrome c reductase 
(specific for complexes II and III) was the enzyme that was the most sensitive to propofol exposure 
in skeletal and heart muscle homogenates even at the lowest used concentrations (20 and 25 M, 
resp.) and in liver at the higher concentration of propofol (40 µM)133. In contrast, the activities of 
the individual complexes (I, II, III) were not affected133. Complex IV was the only enzyme of 
respiratory chain that was decreased by propofol exposure (from concentration  40 M)133. 
Vanlander et al. also performed in vitro experiments using control samples taken from rats before 
the drug was administered133. Samples (skeletal muscle homogenates) were exposed for a short 
time (3 min) to different concentrations of propofol (100; 200 and 400 M) and all above-
mentioned spectrophotometric analyses were repeated. The results showed no significant impact 
of lower doses of propofol (100 M) on activities of respiratory chain complexes133. These results 
were contrary to previously described in vivo experiments demonstrating inhibition (especially of 
complex II+III activity) caused even by 20 M propofol in skeletal muscle. Only at a 10-fold higher 
concentration of propofol (200 M), an inhibitory effect on the respiratory chain activities 
(complex I, complex II+III, complex III and complex IV) was seen in vitro133. An inhibition of complex 
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II activity was seen only after exposure of 400 M propofol133. However, in vivo experiments 
observing long-term effect of propofol sedation reflected more physiological conditions than 
influence of multiple-fold higher (100 M) concentration of propofol on mitochondria after only 
3 minutes of duration. The authors explain the difference between in vivo and in vitro effects by 
different distribution of propofol within mitochondria and different incubation time (in the in vivo 
experiments at the range of hours in comparison with only 3 minutes preincubation in the in vitro 
experiments)133. A significant decline in activity of complex II+III after propofol exposure seen in 
in vivo experiments contrasted with analyses of individual activities of complex II and III 
demonstrating no decrease. Vanlander et al. explained that this could be a consequence of 
possible interference of propofol with Coenzyme Q because of structural similarities of both 








Figure 26. Structural similarity of propofol and Coenzyme Q133. (A) Molecular structure of 
propofol (2,6-diisopropylphenol); (B) Molecular structure of ubiquinol (reduced form of Coenzyme 
Q). Vanlander et al., 2015133.  
 
Coenzyme Q is a lipophilic molecule located in the inner mitochondrial membrane. It 
consists of a redox active benzoquinone ring conjugated to an isoprenoid chain206. The length of 
chain in humans contains 10 isoprenyl units and is designed CoQ10206. Coenzyme Q shuttles 
electrons from complex I and II and transfers them to complex III of the respiratory chain (see 
Figure 27). Coenzyme Q acts also as an antioxidant and scavenger of reactive oxygen species206. In 
addition, it is involved in other cellular functions: DNA replication and repair through its role in 
pyrimidine synthesis and the regulation of the physicochemical properties of cellular 
membranes207,208. In vivo experiments of the study of Vanlander et al. showed no impact of 
propofol on complex II nor complex III when tested individually133. In comparison with this, 
complex II and III activity was affected suggesting that propofol interferes with Coenzyme Q and 
disrupts electron flow from complex II to complex III. Based on this fact, authors performed a set 
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of experiments with coenzyme Q supplementation in the in vitro experiments133.  To confirm the 
hypothesis of possible propofol interference with Coenzyme Q, authors exposed homogenates to 
propofol for 3 minutes and then tested effect of exogenously added Coenzyme Q: one group was 
supplemented with 0.13 mM Coenzyme Q and the second one by 0.26 mM Coenzyme Q. The 
results showed that inhibition of complex II+III by propofol was preventable with Coenzyme Q 
supplementation, reinforcing the hypothesis of a disturbing effect of propofol on the biologic 
function of coenzyme Q133. Authors summarized, that according in vivo tests propofol probably 
incorporated into the inner mitochondrial membrane where starting to accept the electrons from 
the complexes I and II in the respiratory chain without transferring them to complex III133. In the 
in vitro test, sample was exposed to propofol only for 3 minutes. The contact of drug with the 
sample was therefore shorter and time of exposure might be insufficient for incorporation of the 
molecule into the inner mitochondrial membrane. An additional effect on complex IV can be due 
to the interference of propofol with the cytochrome in complex IV (aa3) and with cytochrome c133.  
Apart from propofol-evoked changes of electron transfer chain, propofol-induced 
inhibition of FAO was discussed as the possible underlying mechanism of PRIS68,116. Patients with 
PRIS developed some clinical signs similar to inborn defects of FAO, including cardiac arrhythmias, 
rhabdomyolysis and skeletal myopathy. In FAO disorders, these abnormalities can be triggered by 
prolonged fasting or low-carbohydrate, ketogenic diet209. One case report described a child 
developing PRIS after simultaneous administration of propofol sedation and ketogenic diet138. In 
addition, children with PRIS were often screened falsely positive for inborn defect of FAO as acyl-
CoA derivatives are elevated in their blood68,111,116 and sometimes these changes normalized in 
PRIS survivors after propofol withdrawal68. One animal study also demonstrated an inhibition of 
the transport of fatty acids into mitochondria at the level of carnitine-acyl transferase I, which is 
an enzyme activated by adenosine monophosphate-activated kinase (AMPK)136. If propofol 
interferes with signalling function of coenzyme Q133, it may attenuate the activation of fatty acid 
oxidation by AMPK210, but other study showed that the activity of this enzyme has been increased 
in the myocardium of propofol-sedated rabbits211. 
In our experimental study “Effects of Propofol on Cellular Bioenergetics in Human Skeletal 
Muscle Cells”, we used an in vitro model of human skeletal muscle and studied the effects of 
propofol on major bioenergetics pathways147. Human myotubes were exposed to propofol 
concentrations in a range 1–10 µg/mL for 96 hours in order to resemble levels achieved in patients 
during sedation in the ICU (1.2–4.5 µg/mL139,140) or during induction of general anaesthesia (10.5 
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µg/mL139). We not only measured activities of individual ETC complexes but also studied effects of 
propofol on bioenergetics in a culture of intact or permeabilized cells by Extracellular Flux 
Analysis147, which we had previously adapted for the use in human myotubes149. 
Duration of propofol infusion seems to be a crucial factor for development of PRIS81. 
According to our meta-analysis of 153 published PRIS case reports, we found that some signs (e.g. 
rhabdomyolysis) occurred more frequently after propofol infusion longer than 96 hours81. 
Therefore, we chose the duration of approximately 96 hours for incubation of cells in propofol. 
Ours is the first study looking at the long-term effects of propofol in an in vitro model of human 
tissue.  
Although the highest propofol concentrations (10 µg/mL) affected mitochondrial and 
protein content, and to some extent also activities of isolated respiratory complexes and cell 
survival, none of these effects were observed for lower concentrations of propofol (2.5 µg/mL)147. 
We even found no inhibition of complexes I and II at the range of propofol concentrations147 and 
complex III and IV were significantly affected only at high concentrations of propofol (10 µg/mL;  
see Table 2 in Results)147.  Yet, even very low concentrations of propofol decreased spare ETC 
capacity, which reflects cellular ability to increase respiration when ATP demands are high147. 
Because activities of individual respiratory complexes were unaffected by low propofol 
concentrations, we exploited propofol effects on electron flow between individual ETC complexes 
or upstream metabolic pathways, which feed electrons into ETC (see Figure 27)147.  
To obtain more information about electron flow between complexes in ETC, we looked 
specifically at our experiment testing both complexes I+II- and complex III-linked respiration (see 
Figure 16 in Methods). According to the results, it seemed that low concentrations of propofol (1 
and 2.5 µg/mL) inhibited respiration linked to complex I+II (see Figure 24 in Results), but at higher 
concentrations there was a trend of propofol-induced direct inhibition of complex III.  
In conclusion, although the results of comparison between respiration linked to complex I+II and 
between complex-III linked respiration were not statistically significant, this trend suggested 
propofol disturbation of electron flow in upstream pathway of Complex III, when tested lower 
concentrations. At higher concentrations propofol seemed to start inhibiting of complex III. Of 
note, we used the artificial substrate duroquinol to measure capacity of complex III147, which 
donates electrons directly to respiratory complex III and bypasses Coenzyme Q, so its inhibition 














Figure 27. Electron transfer chain and major energy metabolism pathways. Note: ACS = Acyl-CoA 
Synthetase; CI = Complex I; CII = Complex II; CIII = Complex III; CIV = Complex IV; CPT = Carnitine 
Palmitoyl Transferase; CACT = Carnitine Acyl CoA Transferase; CoA = Coenzyme A; CoQ = 
Coenzyme Q; Cyt c = Cytochrome C; e- = electron; ETF = Electron Transfer Flavoprotein; FAD = 
Flavin adenine dinucleotide; FAO = Fatty acid oxidation; NAD = Nicotinamide adenine dinucleotide; 
TCA cycle = Tricarboxylic Acid (Krebs) Cycle. Krajčová et al., 2017147. 
 
Looking at upstream metabolic pathways, which feed electrons into ETC, we focused also 
on fatty acid oxidation147. We found a profound inhibition of fatty acid oxidation by Extracellular 
Flux Analysis and confirmed this finding by the use of the [1-14C] palmitate tracer method (see 
Figure 22 in Results)147. Furthermore, abundant NEFA in the media abolished the inhibitory effects 
of propofol on the spare ETC capacity147. Taken together, these data suggest that propofol 
exposure limits spare ETC capacity by inhibiting FAO, rather than by inhibiting respiratory 
complexes or electron transfer within ETC. Data from our in vitro experiments firstly brought direct 
evidence of propofol inhibitory effect on FAO in human cells147. On the other hand, apart from 
measuring the activity of one of FAO enzymes (ACAD) that was unaffected by propofol, we have 
not studied the mechanism of FAO inhibition any further147. Propofol (or its intracellular 
metabolites) may inhibit enzyme involved in fatty acids transport, fatty acid oxidation process or 
electron transfer flavoprotein dehydrogenase (see Figure 27). We think it is less likely that 
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propofol-induced inhibition of FAO is secondary to an inhibition within ETC itself, as we have 
observed that any spare ETC capacity was unaffected if propofol-treated cells were cultured in 
fatty acid rich environment147. However, it should be noted that although the range of total 
propofol concentration we exposed our cells to was in the range of that seen in propofol-sedated 
patients, free propofol concentrations might have been higher due to decreased protein binding 
in culture media as compared to plasma212. In addition, added substances (BSA, palmitate) might 
have influenced propofol activity and confound the results147. 
Supplementation of CoQ may become a promising therapeutic strategy (a propofol 
“antidote”) in the near future133. In our pilot experiments (data not shown), we co-exposed human 
myotubes to propofol and various concentrations of coenzyme Q10 for 4 days. The difficulties were 
observed with dissolvement of this strongly hydrophobic molecule. CoQ10 is only sparingly soluble 
in aqueous solutions and is recommended to dilute it rather in organic solvents such as ethanol 
and dimethyl formamide (DMF)213. These organic solvents themselves can have effects on cells 
and is needed to avoid too high concentrations because of risk of toxicity. The solubility of CoQ10 
in ethanol and DMF is approximately 0.3 and 10 mg/mL, respectively213. With increasing 
concentrations of CoQ10 raises also the amount of solvent, which becomes harmful for cells. 
According to our first results, only lesser concentration of CoQ10 were thoroughly dissolved in small 
amount of DMF but had no preventable effect on respiration in cells co-exposed to both propofol 
and CoQ10. When testing higher concentrations of CoQ10 (~50 µM prepared in DMF), respiration 
was lower in cells exposed to CoQ10 (without propofol) than in control group incubated in fresh 
“Differentiation medium” alone suggesting toxic effect of solvent. In addition, it is well-known that 
CoQ10, as a lipophilic molecule, accumulates in membranes and only its small proportion reaches 
the mitochondria. In addition, much of the CoQ10 in mitochondria is likely to be trapped in the 
outer membrane and doesn’t achieve the respiratory chain located in the mitochondrial inner 
membrane214. One of our aims in future is to expose the cells to analogues of CoQ10 with reduced 
hydrophobicity: e.g. short-chain analogue CoQ2 or synthetic compound idebenone214 (see Figure 
28). We also considered to try incubation in medium supplemented by MitoQ, which is a novel 
orally bioavailable molecule conjugated to the lipophilic triphenyl phosphonium (TPP+) cation215. 
The lipophilic cations are accumulated several hundred-fold by the large membrane potential 
(negative inside) generated by mitochondria during oxidative phosphorylation216,217 and easily get 
into the cell and then further into mitochondria215. However, previous studies showed that MitoQ 





















Figure 28. Mitochondria-targeted and untargeted ubiquinones.  James et al., 2005218. 
 
 
form of MitoQ is poorly oxidized by complex III218. MitoQ acts as an effective antioxidant but has 
no effect on respiration218.   
In other sets of out pilot experiments, we started to deal with fatty acid oxidation in detail 
and focused on fatty acid metabolism and co-exposed myotubes to both propofol and carnitine 
(data not shown). Long-term carnitine supplementation (at range of 0.1 to 10 mM) didn’t show 
any impact on respiration. However, we performed only initial set of experiments and effect of 
propofol on both fatty acid transport and oxidation still needs to be examined as we tested only 
the activity of one of FAO (ACAD). The palmitate as the substrate for FAO is at the beginning of 
the metabolic pathway including enzymes of fatty acid transport through outer and inner 
mitochondrial membrane, fatty acid oxidation and ETF dehydrogenase (see Figure 27). In future, 
we plan to test individual enzymes using different substrates for fatty acid transport (e.g. 
palmitate to test Acyl-CoA Synthetase, palmitoyl-CoA to test Carnitine Palmitoyl Transferase 1, 
palmitoyl-carnitine and acetyl-carnitine to test Carnitine Acyl CoA Translocase) and fatty acid 
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oxidation itself (by supplementation of butyrate, hexanoate or octanoate). The comparison 
between respiration using different substrates could reveal a defect in one of the enzymes. In 
addition, we would like to assess spectrophotometrically the activities of individual enzymes. We 
also tried to analyse the activity of ETF dehydrogenase, but it is needed to use a purified enzyme. 
We discussed the method with the colleagues abroad who eventually used bacterium Paracoccus 
denitrificans rather than human, because the human form proved difficult to work with. Generally, 
in case of ETF dehydrogenase, the purification process is extremely difficult and not routinely 
performed.  
Finally, we have recently started with cultivation of human cardiomyocytes isolated from 
left ventricular myocardium obtained at Transplantation Centre of Institute of Clinical and 
Experimental Medicine in Prague from brain-dead donors without cardiac disease, whose hearts 
were not suitable for transplantation due to donor age. We believe that the model of human 
cardiac muscle cells could be the best for in vitro studying PRIS as arrhythmias and cardiac failure 
remain one of the most common signs of PRIS. In future, we would like to expose cardiomyocytes 
to a range of propofol concentrations and looked at all above mentioned possible propofol-
induced changes of mitochondrial metabolism preferentially in these cells. We are also performing 
a set of experiments comparing propofol effect on human and rat skeletal and heart muscle 
homogenates using high resolution respirometry (the method is based on monitoring oxygen 
consumption in the closed chamber). We adapted the technique to measurement of human 
skeletal146 and heart5 muscle tissue homogenates to acquire a simple model for testing drug-

















We firstly analysed all the case reports and case series about PRIS (published between 1990-
2014)81. PRIS may occur even after short duration of infusion and with moderate doses (<4 mg/kg 
per hour) and its diagnosis may be challenging as most typical symptoms are missing81. Overall 
mortality in reported cases of PRIS is 51 % and is decreasing over time81. Propofol infusion rate 
and duration, the presence of trauma brain injury and fever are risk factors independently 
associated with mortality in reported cases of patients with PRIS81. Metabolic acidosis and heart 
failure occur early and depend on the dose of propofol, whilst rhabdomyolysis, arrhythmia and 
other ECG changes are rather dependent on the duration of propofol infusion81. Experimental data 
suggest that early, dose-dependent signs may be caused by inhibition or uncoupling of respiratory 
chain, whilst late, time-dependent signs by inhibition of fatty acid oxidation81. 
In an in vitro study, we were the first, who exposed human cells to propofol for a long-
term period reflecting the conditions when PRIS occurs most likely72,76 and after that we assessed 
the bioenergetic profile147. We not only measured activities of individual ETC complexes but also 
studied effects of propofol on bioenergetics in a culture of intact or permeabilized cells by 
extracellular flux analysis, which we had previously adapted for the use in human myotubes149. 
96-hours of exposure of human skeletal muscle cells to a range of propofol  concentrations 
reduced the spare capacity of electron transfer chain and caused a significant inhibition of fatty 
acid oxidation, which was found by two independent methods (Extracellular Flux Analysis and [1-
14C] palmitate tracer technique)147. 
We chose skeletal muscle being a large body compartment comprising around 40% of total 
body mass and because it is directly affected in PRIS147. It remains unclear how propofol affects 
bioenergetics in other human tissues and organs and whether any metabolic effects would be 











1.  Pagliarini D, Rutter J. Hallmarks of a new era in mitochondrial biochemistry. Genes Dev. 
2013;27:2615-2627. 
2.  Meyer JN, Leung MCK, Rooney JP, et al. Mitochondria as a target of environmental toxicants. 
Toxicol Sci. 2013;134(1):1-17.  
3.  Scheffler IE. Mitochondria.; the second edition, 2008. 
4.  Junior HM. Milestones in the History of Empirical Sciences.; 2012. 
5.  Krajčová A, Megvinet D, Urban T, et al. High resolution respirometry to assess function of 
mitochondria in native homogenates of human heart muscle. Circ Res (under Rev). 2018. 
6.  Vuda M, Kamath A. Drug induced mitochondrial dysfunction: Mechanisms and adverse clinical 
consequences. Mitochondrion. 2016;31:63-74.  
7.  Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev. 
2002;54(1):101–127. 
8.  Wallace K. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. 
Cardiovasc Toxicol. 2007;7:101–107. 
9.  Kudin AP, Mawasi H, Eisenkraft A, Elger CE, Bialer M, Kunz WS. Mitochondrial liver toxicity of 
valproic acid and its acid derivatives is related to inhibition of α-lipoamide dehydrogenase. Int 
J Mol Sci. 2017;18(9):1-11.  
10.  Komulainen T, Lodge T, Hinttala R, et al. Sodium valproate induces mitochondrial respiration 
dysfunction in HepG2 in vitro cell model. Toxicology. 2015;331:47-56. 
11.  Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. 
Expert Opin Drug Saf. 2006;5(5):651-666. 
12.  Schirris TJJ, Renkema GH, Ritschel T, et al. Statin-induced myopathy is associated with 
mitochondrial complex III inhibition. Cell Metab. 2015;22(3):399-407.  
13.  Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. 
Ochsner J. 2010;10(1):16-21.  
14.  Nawarskas J. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13(2):76-79. 
15.  Fromenty B, Fisch C, Labbe G, et al. Amiodarone inhibits the mitochondrial beta-oxidation of 
fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther. 
1990;255(3):1371-1376. 
16.  Kennedy J, Unger S, Horowitz J. Inhibition of carnitine palmitoyltransferase-1 in rat heart and 
liver by perhexiline and amiodarone. Biochem Pharmacol. 1996;52(2):273-280. 
17.  Chatzispyrou I, Held N, Mouchiroud L, Auwerx J, Houtkooper R. Tetracycline antibiotics impair 
mitochondrial function and its experimental use confounds research. Cancer Res. 
2015;75(21):4446-4449. 
18.  Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of 
hepatotoxicity. Pharmacol Ther. 1995;67(1):101-154. 
19.  Li C, Cheng Y, Liao P, Yang Y, Kang J. Chloramphenicol causes mitochondrial stress, decreases 
86 
 
ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell 
invasion. Toxicol Sci. 2010;116(1):140-150. 
20.  Glasgow JFT, Y BM, Moore R, Gray A, Hill J. The mechanism of inhibition of L -oxidation by aspirin 
metabolites in skin broblasts from Reye's syndrome patients and controls. Biochim Biophys 
Acta. 1999;1454:115-125. 
21.  Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects 
through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 
2000;614:607-614.  
22.  Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW. Predictors of mortality in 
patients with suspected propofol infusion syndrome. Crit Care Med. 2008;36(8):2281-2287.  
23.  Rogers KM, Dewar KM, McCubbin TD, Spence  a a. Preliminary experience with ICI 35 868 as an 
i.v. induction agent: comparison with althesin. Br J Anaesth. 1980;52(8):807-810.  
24.  Rutter D V, Morgan M, Lumley J, Owen R. ICI 35 868 (Diprivan): A new intravenous induction 
agent—A comparison with methohexitone. Anaesthesia. 1980;35:1188-1192. 
25.  Yip GMS, Chen Z-W, Edge CJ, et al. A propofol binding site on mammalian GABAA receptors 
identified by photolabeling. Nat Chem Biol. 2013;9(11):715-720.  
26.  Lalwani K, Michel M. Pediatric sedation in North American children’s hospitals: A survey of 
anesthesia providers. Paediatr Anaesth. 2005;15(3):209-213.  
27.  Edelist G. A comparison of propofol and thiopentone as induction agents in outpatient surgery. 
Can J Anaesth. 1987;34(2):110-116.  
28.  Bahar M, Dundee JW, O&apos;Neill MP, Briggs LP, Moore J, Merrett JD. Recovery from 
intravenous anaesthesia. Comparison of disoprofol with thiopentone and methohexitone. 
Anaesthesia. 1982;37(12):1171-1175.  
29.  Grounds RM, Lalor JM, Lumley J, Royston D, Morgan M. Propofol infusion for sedation in the 
intensive care unit: preliminary report. Br Med J (Clin Res Ed). 1987;294(6569):397-400. 
30.  Kelly D, Goodale D, Williams J, et al. Propofol in the treatment of moderate and severe head 
injury: a randomized, prospective double-blinded pilot trial. J Neurosurg. 1999;90(6):1042-
1052.  
31.  Ronan KP, Gallagher TJ, George B, Hamby B. Comparison of propofol and midazolam for 
sedation in intensive care unit patients. Crit Care Med. 1995;23(2):286-293.  
32.  Notis fra Bivirkningsnaenet. Propofol (Diprivan) bivirkninger. Ugeskr Laeger. 152:1176. 
33.  Parke TJ, Stevens JE, Rice  a S, et al. Metabolic acidosis and fatal myocardial failure after 
propofol infusion in children: five case reports. BMJ. 1992;305(6854):613-616.  
34.  Chidambaran V, Costandi A, D’Mello A. Propofol: a review of its role in pediatric anesthesia and 
sedation. CNS Drugs. 2016;29(7):543-563.  
35.  Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103(4):860-
876. 
36.  Briggs LP, Clarke RSJ, Watkins J. An adverse reaction to the administration of disoprofol ( 
Diprivan ). Anaesthesia. 1982;37:1099-1101. 
37.  http://www.medsafe.govt.nz/profs/Datasheet/d/Diprivaninj.pdf. 
87 
 
38.  Langevin PB, Gravenstein N, Doyle TJ, et al. Growth of Staphylococcus aureus in Diprivan and 
Intralipid. Anesthesiology. 1999;(5):1394-1400. 
39.  Fukada T, Ozaki M. Microbial growth in propofol formulations with disodium edetate and the 
influence of venous access system dead space. Anaesthesia. 2007;62(6):575-580.  
40.  Kanto J, Gepts E. Pharmacokinetic Implications for the Clinical Use of Propofol. Clin 
Pharmacokinet. 1989;17(5):308-326. 
41.  Thompson KA, Goodale DB. The recent development of propofol (DIPRIVAN). Intensive Care 
Med. 2000;26(Suppl 4):S400-4. 
42.  James R, Glen J. Synthesis, biological evaluation, and preliminary structure-activity 
considerations of a series of alkylphenols as intravenous anesthetic agents. J Med Chem. 
1980;23(12):1350-1357. 
43.  Kay B, Rolly G. Dosage of ici 35 868. Br J Anaesth. 1981;53(2):192-193. 
44.  Schnider T, Minto C, Shafer S, et al. The influence of age on propofol pharmacodynamics. 
Anesthesiology. 1999;90(6):1502-1516. 
45.  Khan KS, Hayes I, Buggy DJ. Pharmacology of anaesthetic agents I: intravenous anaesthetic 
agents. Anaesthesia, Crit Care Pain. 2014;14(3):100-105.  
46.  Duke T. A new intravenous anesthetic agent: Propofol. Can Vet J. 1995;36(3):181-183.  
47.  Glen JB. Animal Studies of the Anaesthetic Activity of Diprivan (Ici 35, 868). Vet Anaesth Analg. 
1978;8(1):138-140.  
48.  Smith S, Scarth E, Sasada M. Drug in Anaesthesia and Intensive Care.; 2011. 
49.  Hardman JG, Hopkins PM, Struys MMR. Oxford Textbook of Anaesthesia.; 2017. 
50.  Shaw I, Kumar C, Dodds C. Oxford Textbook of Anaesthesia for Oral and Maxillofacial Surgery.; 
2010. 
51.  Shafer SL. Advances in propofol pharmacokinetics and pharmacodynamics. J Clin Anesth. 
1993;(suppl 1):14S-21S. 
52.  Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem. 
2012;287(48):40224-40231.  
53.  Ito H, Watanabe Y, Isshiki A, Uchino H. Suppression of parasympathetic reflex vasodilatation in 
the lower lip of the cat by isoflurane, propofol, ketamine and pentobarbital: implications for 
mechanisms underlying the production of anaesthesia. Br J Anaesth. 1998;81:563–568. 
54.  Zhan R, Qi S, Wu C, Fujihara H, Taga K, Shimoji K. Intravenous anesthetics differentially reduce 
neurotransmission damage caused by oxygen-glucose deprivation in rat hippocampal slices in 
correlation with N-methyl-D-aspartate receptor inhibition. Crit Care Med. 2001;29:808–813. 
55.  Sitar S, Hanifi-Moghaddam P, Gelb A, Cechetto D, Siushansian R, Wilson J. Propofol prevents 
peroxide-induced inhibition of glutamate transport in cultured astrocytes. Anesthesiology. 
1999;90:1446-1453. 
56.  MCA/CSM. Serious adverse effects and fatalities in children associated with the use of propofol 
(Diprivan) for sedation. Curr Probl Pharmacovilance. 34:4.  
57.  Rosen DJ, Nicoara A, Koshy N, Wedderburn R V. Too much of a good thing? Tracing the history 
of the propofol infusion syndrome. J Trauma. 2007;63(2):443-447.  
88 
 
58.  Ahlen K, Buckley CJ, Goodale DB, Pulsford AH. The “propofol infusion syndrome”: The facts, 
their interpretation and implications for patient care. Eur J Anaesthesiol. 2006;23(12):990-998.  
59.  US Food and Drug Administration, Center for Drug Evaluation and Research (Anesthetic and Life 
Support Committee). ICI’s Diprivan® (propofol) anesthetic has no link to pediatric deaths in 
ICUs. FDC Reports 1992, Sep 7;54: FDC Reports. 1992;Sep 7;(54:):14. 
60.  Barclay K, Williams AJ, Major E. Propofol infusion in children. BMJ. 1992;305(6859):953-954. 
61.  Bodd E, Endresen L. Use of propofol for children. Tidsskr Nor Laegeforen. 1992;112:1636–7. 
62.  Kirkpatrick M, Cole G. Propofol infusion in children. BMJ. 1992;305(6863):1223. 
63.  Martin PH, Murthy B V, Petros  a J. Metabolic, biochemical and haemodynamic effects of 
infusion of propofol for long-term sedation of children undergoing intensive care. Br J Anaesth. 
1997;79(3):276-279.  
64.  Bray RJ. Fatal Myocardial Failure Associated With a Propofol Infusion in a Child. Anaesthesia. 
1995;50(1):94. 
65.  Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth. 1998;8(6):491-499.  
66.  Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol 
infusion in children. Neurology. 1998;50(1):301-303.  
67.  Mehta N, DeMunter C, Habibi P, Nadel S, Britto J. Short-term propofol infusions in children. 
Lancet. 1999;354(9181):866-867.  
68.  Wolf A, Weir P, Segar P, Stone J. Impaired fatty acid oxidation in propofol infusion syndrome. 
Lancet. 2001;357:606-607. 
69.  FDA issues warning on propofol (Diprivan). CMAJ. 164(11):1608. 
70.  Kill C, Leonhardt A, Wulf H. Lactic acidosis after short-term infusion of propofol for anaesthesia 
in a child with osteogenesis imperfecta. Paediatr Anaesth. 2003;13(9):823-826.  
71.  Stelow EB, Johari VP, Smith SA, Crosson JT, Apple FS. Propofol-associated rhabdomyolysis with 
cardiac involvement in adults: Chemical and anatomic findings. Clin Chem. 2000;46(4):577-581. 
72.  Cremer OL, Moons KGM, Bouman E a C, Kruijswijk JE, Smet AMG a De, Kalkman CJ. Long-term 
propofol infusion and cardiac failure in adult head-injured patients. Lancet. 
2001;357(9250):117-118.  
73.  Perrier ND, Baerga-Varela Y, Murray MJ. Death related to propofol use in an adult patient. Crit 
Care Med. 2000;28(8):3071-3074.  
74.  Marinella MA. Lactic acidosis associated with propofol. Chest. 1996;109(1):292. 
75.  Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother. 
2002;36(9):1453-1456. 
76.  Jacobi J, Fraser GL, Coursin DB, et al. Analgesics in the Critically Ill Adult. Crit Care Med. 
2002;30(1):119-141. 
77.  U.S. Food and Drug Administration. MedWatch. Detailed view: safety labeling changes 
approved by FDA Center for Drug Evaluation and Research (CDER)—February 2007. Diprivan 
(propofol) injectable emulsion for IV administration. 2007. 




79.  Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: 
A simple name for a complex syndrome. Intensive Care Med. 2003;29(9):1417-1425.  
80.  Kam PCA, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007;62(7):690-701.  
81.  Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of 
experimental studies and 153 published case reports. Crit Care. 2015;19(1):398.  
82.  Chukwuemeka A, Ko R, Ralph-Edwards A. Short-term low-dose propofol anaesthesia associated 
with severe metabolic acidosis. Anaesth Intensive Care. 2006;34(5):651-655. 
83.  Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in 
critically ill adults: a prospective, multicenter study. Crit Care. 2009;13(5):R169.  
84.  Richter S, Brugada P. Propofol-induced coved-type electrocardiogram during catheter ablation 
of paroxysmal atrial fibrillation: A case of Brugada syndrome? Herzschrittmachertherapie und 
Elektrophysiologie. 2012;23(1):56-58.  
85.  Schroeppel TJ, Fabian TC, Clement LP, et al. Propofol infusion syndrome: A lethal condition in 
critically injured patients eliminated by a simple screening protocol. Injury. 2014;45(1):245-249.  
86.  Linko R, Laukkanen A, Koljonen V, Rapola J, Varpula T. Severe Heart Failure and Rhabdomyolysis 
Associated With Propofol Infusion in a Burn Patient. J Burn Care Res. 2014;35(5):E364-E367.  
87.  Cravens GT, Packer DL, Johnson ME. Incidence of propofol infusion syndrome during 
noninvasive radiofrequency ablation for atrial flutter or fibrillation. Anesthesiology. 
2007;106(6):1134-1138.  
88.  Smith H, Sinson G, Varelas P. Vasopressors and propofol infusion syndrome in severe head 
trauma. Neurocrit Care. 2009;10(2):166-172.  
89.  Iyer VN, Hoel R, Rabinstein A a. Propofol infusion syndrome in patients with refractory status 
epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37(12):3024-3030.  
90.  Plotz FB, Waalkens HJ, Verkade HJ, Strengers JL, Knoester H MJ. Fatal side-effects of continuous 
propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive 
Care. 1996;24(6):724. 
91.  Vernooy K, Delhaas T, Cremer OL, et al. Electrocardiographic changes predicting sudden death 
in propofol-related infusion syndrome. Hear Rhythm. 2006;3(2):131-137.  
92.  Weiner JB, Haddad E V., Raj SR. Recovery following propofol-associated brugada 
electrocardiogram. PACE - Pacing Clin Electrophysiol. 2010;33(4):1-7.  
93.  Robinson JDC, Melman Y, Walsh EP. Cardiac conduction disturbances and ventricular 
tachycardia after prolonged propofol infusion in an infant. PACE - Pacing Clin Electrophysiol. 
2008;31(8):1070-1073. 
94.  Koch M, De Backer D, Vincent JL. Lactic acidosis: An early marker of propofol infusion 
syndrome? Intensive Care Med. 2004;30(3):522.  
95.  Holzki J, Aring C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: A case 
report. Paediatr Anaesth. 2004;14(3):265-270.  
96.  Burow BK, Johnson ME, Packer DL. Metabolic acidosis associated with propofol in the absence 
of other causative factors. Anesthesiology. 2004;101(1):239-241.  
97.  Romero P C, Morales R M, Donaire R L, et al. Acidosis láctica severa asociada a infusión de 
propofol. Caso clínico. Rev Med Chil. 2008;136(1):88-92. 
90 
 
98.  Laquay N, Prieur S, Greff B, Meyer P, Orliaguet G. Le syndrome de perfusion du propofol. Ann 
Fr Anesth Reanim. 2010;29(5):377-386. 
99.  Mali AR, Patil VP, Pramesh CS, Mistry RC. Hyperkalemia during surgery: Is it an early warning of 
propofol infusion syndrome? J Anesth. 2009;23(3):421-423.  
100.  Aloizos S, Gourgiotis S, Oikonomou K, Stakia P. Acute renal failure and rhabdomyolysis in a 
patient with infectious mononucleosis: a case report. Cases J. 2008;1(1):222.  
101.  Fudickar A, Tonner PH, Mihaljovic Z, et al. Suggested beginning of propofol infusion syndrome 
in an adult patient without lactacidosis: a case report. Eur J Anaesthesiol. 2008;25(9):777-778.  
102.  Vokes DE, Linskey ME AW. Propofol lipemia mimicking chyle leak during neck dissection. Head 
Neck. 2006;28(12):1147-9. 
103.  Otterspoor LC, Kalkman CJ, Cremer OL. Update on the propofol infusion syndrome in ICU 
management of patients with head injury. Curr Opin Anaesthesiol. 2008;21(5):544-551.  
104.  Gottschling S, Meyer S, Krenn T, Kleinschmidt S, Reinhard H, Graf N SG. Effects of short-term 
propofol administration on pancreatic enzymes and triglyceride levels in children. Anaesthesia. 
2005;60(7):660-3. 
105.  Cray S. Fat metabolism during propofol infusion. Br J Anaesth. 1999;82(3):473. 
106.  Orsini J, Nadkarni A, Chen J, Cohen N. Propofol infusion syndrome: Case report and literature 
review. Am J Heal Pharm. 2009;66(10):908-915.  
107.  Cray SH, Robinson BH CP. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. 
Crit Care Med. 1998;26:2087–2092. 
108.  Sammartino M, Garra R, Sbaraglia F, Papacci P. Propofol overdose in a preterm baby: May 
propofol infusion syndrome arise in two hours? Paediatr Anaesth. 2010;20(10):973-974.  
109.  Sabsovich BI, Rehman Z, Yunen J, Coritsidis G, Surgical F. Propofol Infusion Syndrome: a Case of 
Incresing Morbidity With Traumatic Brain Injury. Am J Crit care. 2007;16(1):82-85. 
110.  Guitton C, Gabillet L, Latour P, et al. Propofol infusion syndrome during refractory status 
epilepticus in a young adult: Successful ECMO resuscitation. Neurocrit Care. 2011;15(1):139-
145.  
111.  Fodale V, Monaca E La. Propofol infusion syndrome: an overview of a perplexing disease. Fodale 
V, La Monaca E. Drug Saf. 2008; 31(4):293-303.  
112.  Zarovnaya EL, Jobst BC, Harris BT. Propofol-associated fatal myocardial failure and 
rhabdomyolysis in an adult with status epilepticus. Epilepsia. 2007;48(5):1002-1006.  
113.  Jorens PG, Van den Eynden GG. Propofol Infusion Syndrome With Arrhythmia, Myocardial Fat 
Accumulation and Cardiac Failure. Am J Cardiol. 2009;104(8):1160-1162.  
114.  Shimony A, Almog Y, Zahger D. Propofol infusion syndrome: A rare cause of multi-organ failure 
in a man with complicated myocardial infarction. Isr Med Assoc J. 2008;10(4):316-317. 
115.  Ernest D, French C. Propofol infusion syndrome--report of an adult fatality. Anaesth Intensive 
Care. 2003;31(3):316-319. 
116.  Withington DE, Decell MK, Al Ayed T. A case of propofol toxicity: Further evidence for a causal 
mechanism. Paediatr Anaesth. 2004;14(6):505-508.  
117.  Casserly B, O’Mahony E, Timm EG, Haqqie S, Eisele G, Urizar R. Propofol infusion syndrome: an 
91 
 
unusual cause of renal failure. Am J Kidney Dis. 2004;44(6):e98-e101.  
118.  Liolios A, Guérit JM, Scholtes JL, Raftopoulos C, Hantson P. Propofol infusion syndrome 
associated with short-term large-dose infusion during surgical anesthesia in an adult. Anesth 
Analg. 2005;100(6):1804-1806.  
119.  Corbett SM, Moore J, Rebuck J a, Rogers FB, Greene CM. Survival of propofol infusion syndrome 
in a head-injured patient. Crit Care Med. 2006;34(9):2479-2483.  
120.  Karakitsos D, Poularas J, Kalogeromitros A, Karabinis A. The propofol infusion syndrome treated 
with haemofiltration. Is there a time for genetic screening? Acta Anaesthesiol Scand. 
2007;51(5):644-645.  
121.  Pisapia JM, Wendell LC, Kumar MA, Zager EL, Levine JM. Lactate-to-pyruvate ratio as a marker 
of propofol infusion syndrome after subarachnoid hemorrhage. Neurocrit Care. 
2011;15(1):134-138.  
122.  Poretti A, Bosemani T, Huisman TAGM. Neuroimaging findings in pediatric propofol infusion 
syndrome. Pediatr Neurol. 2014;50(4):431-432.  
123.  Imam TH. Propofol-related infusion syndrome: role of propofol in medical complications of 
sedated critical care patients. Perm J. 2013;17(2):85-87. 
124.  Menon DK, Matta BF, Gupta AK SA. Propofol use in head-injury patients. Lancet. 
2001;357(9269):1708-9; 
125.  Machata  a M, Gonano C, B??rsan T, Zimpfer M, Spiss CK. Rare but Dangerous Adverse Effects 
of Propofol and Thiopental in Intensive Care. J Trauma Inj Infect Crit Care. 2005;58(3):643-645.  
126.  Barbara DW WFJ. Propofol induction resulting in green urine discoloration. Anesthesiology. 
2012. 116(4):924. 116AD;(4):924. 
127.  Da-Silva SS, Wong R, Coquillon P, Gavrilita C, Asuncion A. Partial-exchange blood transfusion: 
an effective method for preventing mortality in a child with propofol infusion syndrome. 
Pediatrics. 2010;125(6):e1493-e1499.  
128.  Branca D, Roberti MS, Lorenzin P, Vincenti E SG. Influence of the anesthetic 2,6-
diisopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem 
Pharmacol. 1991;42(1):87-90. 
129.  Branca D, Vincenti E SG. Influence of the anesthetic 2,6-diisopropylphenol (propofol) on 
isolated rat heart mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 
1995;110(1):41-5. 
130.  Rigoulet M, Devin A, Avéret N, Vandais B, Guérin B. Mechanisms of inhibition and uncoupling 
of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. 
Eur J Biochem. 1996;241(1):280-285. 
131.  Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused 
guinea pig hearts determined by reflectance spectroscopy. Crit Care Med. 200;28(1):172-7. 
132.  Branca D, Roberti MS, Vincenti E SG. Uncoupling effect of the general anesthetic 2,6-
diisopropylphenol in isolated rat liver mitochondria. Arch Biochem Biophys. 1991;290(2):517-
21. 
133.  Vanlander AV, Okun JG, de Jaeger A, Smet J, De Latter E, De Paepe B, Dacremont G, Wuyts B, 
Vanheel B, De Paepe P, Jorens PG, Van Regenmortel N VCR. Possible pathogenic mechanism of 
propofol infusion syndrome involves coenzyme q. Anesthesiol. 2015;122(2)343-52.  
92 
 
134.  Wolf AR, Potter F. Propofol infusion in children: When does an anesthetic tool become an 
intensive care liability? Paediatr Anaesth. 2004;14(6):435-438.  
135.  Rinaldo P, Cowan TM MD. Acylcarnitine profile analysis. Genet Med. 2008;(10(2):):151-6. 
136.  Tong XX, Kang Y, Liu FZ, Zhang WS LJ. [Effect of prolonged infusion of propofol on the liver 
mitochondria respiratory function in rabbits]. Sichuan Da Xue Xue Bao Yi Xue Ban. 
2010;41(6):1021-3. 
137.  Jiang W, Yang ZB, Zhou QH, Huan X, Wang L. Lipid metabolism disturbances and AMPK 
activation in prolonged propofol-sedated rabbits under mechanical ventilation. Acta Pharmacol 
Sin. 2012;33(1):27-33.  
138.  Baumeister F, Oberhoffer R, Liebhaber G, et al. Fatal propofol infusion syndrome in association 
with ketogenic diet. Neuropediatrics. 2004;(35(4):):250-2. 
139.  Herregods L, Rolly G, Versichelen L, Rosseel MT. Propofol combined with nitrous oxide-oxygen 
for induction and maintenance of anaesthesia. Anaesthesia. 1987;42(4):360-365. 
140.  Casati A, Fanelli G, Casaletti E, Colnaghi E, Cedrati V, Torri G. Clinical assessment of target-
controlled infusion of propofol during monitored anesthesia care. Can J Anaesth. 
1999;46(3):235-239.  
141.  Gong Y, Li E, Xu G, et al. Investigation of propofol concentrations in human breath by solid-
phase microextraction gas chromatography-mass spectrometry. J Int Med Res. 
2009;37(5):1465-1471.  
142.  Kumar M, Urrutia V, Thomas C, Abou-Khaled K, Schwartzman R. The syndrome of irreversible 
acidosis after prolonged propofol infusion. Neurocrit Care. 2005;3(3):257-259. 
143.  Merz TM, Regli B, Rothen HU FP. Propofol infusion syndrome--a fatal case at a low infusion rate. 
Anesth Analg. 2006;103(4):1050. 
144.  Culp KE, Augoustides JG, Ochroch AE, Milas BL. Clinical Management of Cardiogenic Shock 
Associated with Prolonged Propofol Infusion. Anesth Analg. 2004;99(1):221-226.  
145.  Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical 
research. Scand J Clin Lab Invest. 1975;35(7):609-616. 
146.  Ziak J, Krajcova A, Jiroutkova K, Nemcova V, Dzupa V, Duska F. Assessing the function of 
mitochondria in cytosolic context in human skeletal muscle: Adopting high-resolution 
respirometry to homogenate of needle biopsy tissue samples. Mitochondrion. 2015;21:106-
112. 
147.  Krajčová A, Løvsletten NG, Waldauf P, et al. Effects of Propofol on Cellular Bioenergetics in 
Human Skeletal Muscle Cells. Crit Care Med. 2018;46(3):e206-e212. 
148.  Thompson D, Pratley R, Ossowski V. Human primary myoblast cell cultures from non-diabetic 
insulin resistant subjects retain defects in insulin action. J Clin Invest. 1996;98(10):2346-2350. 
149.  Krajcova A, Ziak J, Jiroutkova K, et al. Normalizing glutamine concentration causes 
mitochondrial uncoupling in an in vitro model of human skeletal muscle. JPEN J Parenter Enteral 
Nutr. 2015;39(2):180-189.  
150.  http://www.zen-bio.com/pdf/ZBM0044.pdf. 
151.  Reitzer L, Wice B, Kennell D. Evidence that glutamine, not sugar, is the major energy source for 
cultured HeLa cells. J Biol Chem. 1979;254:2669-2676. 
93 
 
152.  Hou Y, Chiu W, Yeh C, Yeh S. Glutamine modulates lipopolysaccharide-induced activation of NF-
κB via the Akt/mTOR pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 
2012;302(1):L174-L183. 
153.  Yuneva M, Zamboni N, Oefner P, Sachidanandam, R Lazebnik Y. Deficiency in glutamine but not 
glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178:93-105. 
154.  Labitzke R, Friedl P. A serum-free medium formulation supporting growth of human umbilical 
cord vein endothelial cells in long-term cultivation. Cytotechnology. 2001;35:87-92. 
155.  Aguer C, Foretz M, Lantier L, et al. Increased FAT/CD36 cycling and lipid accumulation in 
myotubes derived from obese type 2 diabetic patients. PLoS One. 2011;6(12).  
156.  Fisher H, Yeh J. Contact inhibition in colony formation. Science. 1967;155(3762):581-582. 
157.  Pappas D. Practical Cell Analysis.; 2010. 
158.  http://catalog.takara-bio.co.jp/PDFFiles/AA-1039-7_0411(inst)_j.pdf. 
159.  http://www.medsafe.govt.nz/profs/datasheet/i/Intralipidinf.pdf. 
160.  Warltier DC, Ph D. Ⅵ review articles. 2016;(4):860-876. 
161.  Edwards LM, Lawler NG, Nikolic SB, et al. Metabolomics reveals increased isoleukotoxin diol ( 
12 , 13-DHOME ) in human plasma after acute Intralipid infusion. J Lipid Res. 2012; 53(9):1979-
86 
162.  Lou P, Lucchinetti E, Zhang L, et al. The Mechanism of Intralipid H -Mediated Cardioprotection 
Complex IV Inhibition by the Active Metabolite , Palmitoylcarnitine , Generates Reactive Oxygen 
Species and Activates Reperfusion Injury Salvage Kinases. PLoS One. 2014; Jan 30;9(1):e87205.  
163.  Patková J, Anděl M, Trnka J. Palmitate-induced cell death and mitochondrial respiratory 
dysfunction in myoblasts are not prevented by mitochondria-targeted antioxidants. Cell Physiol 
Biochem. 2014;33(5):1439-1451. 
164.  http://www.seahorsebio.com/resources/tech-writing/protocol-bsa-palmitate.pdf.  
165.  Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of Mitochondrial Oxidative 
Phosphorylation in Patient Muscle Biopsies, Lymphoblasts, and Transmitochondrial Cell Lines. 
Methods Enzymol. 1996;264(1992):484-509. 
166.  Cory AH, Owen TC, Barltrop JA CJ. Use of an aqueous soluble tetrazolium/formazan assay for 
cell growth assays in culture. Cancer Commun. 1991;3(7):207-212. 
167.  Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 
2011;435(2):297-312.  
168.  Wu M, Neilson A, Swift A, et al. Multiparameter metabolic analysis reveals a close link between 
attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human 
tumor cells. Am J Physiol Cell Physiol. 2007;292(1):125-136. 
169.  Gerencser AA, Neilson A, Choi SW, et al. Quantitative microplate-based respirometry with 
correction for oxygen diffusion. Anal Chem. 2009;81(16):6868-6878.  
170.  Choi S, Gerencser A, Nicholls D. Bioenergetic analysis of isolated cerebrocortical nerve terminals 
on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J 
Neurochem. 2009;109(4):1179-1191. 
171.  Wikstrom JD, Sereda SB, Stiles L, et al. A novel high-throughput assay for islet respiration reveals 
94 
 




173.  http://www.bioblast.at/index.php/State_1. 
174.  http://www.bioblast.at/index.php/Residual_oxygen_consumption. 
175.  http://www.bioblast.at/index.php/Proton_leak. 
176.  http://www.bioblast.at/index.php/LEAK_respiration. 
177.  http://www.bioblast.at/index.php/ET-capacity. 
178.  Overview T. Using PMP to Measure Substrate Specific ETC / OxPhos Activity in Permeabilized 
Cells. :1-6. 
179.  Shourie A. Bioanalytical Techniques.; 2005. 
180.  Jamur M, Oliver C. Permeabilization of cell membranes. Methods Mol Biol. 2010;588:63-66. 
181.  McCarthy D, Macey M. Cytometric Analysis of Cell Phenotype and Function.; 2001. 
182.  Salabei JK, Gibb AA, Hill BG. Comprehensive measurement of respiratory activity in 
permeabilized cells using extracellular flux analysis. Nat Protoc. 2014;9:421–438. 
183.  https://www.agilent.com/cs/library/technicaloverviews/public/5991-7157EN.pdf  
184.  https://www.agilent.com/cs/library/usermanuals/public/insert-xf-pmp-reagent-web.pdf. 
185.  Mookerjee SA, Divakaruni AS, Jastroch M, Brand MD. Mitochondrial uncoupling and lifespan. 
Mech Ageing Dev. 2010;131(7-8):463-472. 
186.  http://www.bioblast.at/index.php/Oxidative_phosphorylation. 
187.  Terada H. Uncouplers of Oxidative Phosphorylation. Environ Health Perspect. 1990;87:213-218.  
188.  Chance B, Williams G. A simple and rapid assay of oxidative phosphorylation. Nature. 
1955;25(175(4469)):1120-1121. 
189.  http://www.bioblast.at/index.php/State_3u. 
190.  Hajri T, Abumrad NA. Fatty Acid Transport Across Membranes: Relevance to Nutrition and 




192.  Zhang J, Nuebel E, Wisidagama DRR, et al. Measuring energy metabolism in cultured cells, 
including human pluripotent stem cells and differentiated cells. Nat Protoc. 2012;7(6).  
193.  Srere PA. Citrate Synthase. Methods Enzym. 1969;13:3-11. 
194.  http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma/Bulletin/cs0720bul.pdf. 
195.  Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248-254. 
95 
 
196.  Trnka J, Elkalaf M, Andel M. Lipophilic Triphenylphosphonium Cations Inhibit Mitochondrial 
Electron Transport Chain and Induce Mitochondrial Proton Leak. PLoS One. 2015;10:e0121837-
14. 
197.  Ijlst L. A simple spectrophotometric assay for long-chain acyl-CoA dehydrogenase activity 
measurements in human skin fibroblasts. Ann Clin Biochem. 1993;30:293-297. 
198.  Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356(11):1140-1151. 
199.  Jouven X, Charles M, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as a 
predictive risk factor for sudden death in the population. Circulation. 2001;104(7):756–61. 
200.  Stanley C, Bennett M, Mayatepek E. Inborn Metabolic Diseases. Berlin: Springer Berlin 
Heidelberg; Disorders of Mitochondrial Fatty Acid Oxidation and Related Metabolic Pathways.; 
2006. 
201.  Terrone G, Ruoppolo M, Brunetti-Pierri, N Cozzolino C, et al. Child neurology: recurrent 
rhabdomyolysis due to a fatty acid oxidation disorder. Neurology. 2014;82(1):1-4. 
202.  Heyman M, Storch S, Ament M. The fat overload syndrome. Report of a case and literature 
review. Am J Dis Child. 1981;135(7):628–30. 
203.  Adolph M, Heller A, Koch T, et al. Lipid emulsions—Guidelines on Parenteral Nutrition, Chapter 
6. Ger Med Sci. 2009;7. 
204.  Gura K, Puder M. Rapid infusion of fish oil-based emulsion in infants does not appear to be 
associated with fat overload syndrome. Nutr Clin Pr. 2010;25(4):399–402. 
205.  Ypsilantis P, Politou M, Mikroulis D, et al. Attenuation of propofol tolerance conferred by 
remifentanil co-administration does not reduce propofol toxicity in rabbits under prolonged 
mechanical ventilation. J Surg Res. 2011;168(2):253-261.  
206.  Quinzii C, Hirano M. Coenzyme Q and Mitochondrial Disease. Dev Disabil Res. 2010;16(2):183-
188.  
207.  López-Martín JM, Salviati L, Trevisson E, et al. Missense mutation of the COQ2 gene causes 
defects of bioenergetics and de novo pyrimidine synthesis. Hum Mol Genet. 2007;16(9):1091-7  
208.  Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 
- Biomembr. 2004;1660(1-2):171-199. 
209.  Darras BT, Friedman NR. Metabolic Myopathies : A Clinical Approach ; Part I. 2000;22(2):87-97. 
210.  Lee S, Lee J, Kim J, et al. Coenzyme Q10 increases the fatty acid oxidation through AMPK-
mediated PPARα induction in 3 T3-L1 preadipocytes. Cell Signal. 2012;24(12):2329–36. 
211.  Jiang W1, Yang ZB, Zhou QH, Huan X WL. Lipid metabolism disturbances and AMPK activation 
in prolonged propofol-sedated rabbits under mechanical ventilation. Acta Pharmacol Sin. 
2012;33(1):27-33. 
212.  Dawidowicz A, Kalitynski R, Kobielski M, Pieniadz J. Influence of propofol concentration in 
human plasma on free fraction of the drug. Chem Biol Interact. 2006;159(2):149-155. 
213.  https://www.caymanchem.com/pdfs/11506.pdf. 
214.  Geromel V, Darin N, Chrétien D, et al. Coenzyme Q10 and idebenone in the therapy of 




215.  Cochemé HM, Kelso GF, James AM, et al. Mitochondrial targeting of quinones: Therapeutic 
implications. Mitochondrion. 2007;7:94-102.  
216.  Murphy M, Smith R. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv 
Drug Deliv Rev. 2000;41(2):235-250. 
217.  Smith R, Porteous C, Gane A, Murphy M. Delivery of bioactive molecules to mitochondria in 
vivo. Proc Natl Acad Sci USA. 2003;100(9):5407-5412. 
218.  James AM, Cochemé HM, Smith RAJ, Murphy MP. Interactions of mitochondria-targeted and 
untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species: 
Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol 



























20.1 List of publications 
 
20.1.1   Publications with IF related to the thesis 
Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of 
experimental studies and 153 published case reports.  Crit Care. 2015 Nov 12;19:398. (IF = 4.476) 
Krajčová A, Løvsletten NG, Waldauf P, Frič V, Elkalaf M, Urban T, Anděl M, Trnka J, Thoresen GH, 
Duška F. Effects of Propofol on Cellular Bioenergetics in Human Skeletal Muscle Cells. Crit Care 
Med. 2018 Mar;46(3):e206-e212 (IF = 7.05) 
 
20.1.2 Abstracts related to the thesis 
Krajcova A, Waldauf P, Andel M, Duska F. Mitochondrial pathogenesis of propofol infusion 
syndrome in an in vitro model of human skeletal muscle. MitoFit Science Camp, Kuehtai, Austria, 
2016 Jul 07-13. 
Krajčová A, Waldauf P, Duška F. Mitochondrial pathogenesis of propofol infusion syndrome in an 
in vitro model of human skeletal muscle. 29th Annual Congress of the European Society of 
Intensive Care Medicine, Milan, Italy, 1 - 5 October 2016.  
Krajčová A, Løvsletten NG, Waldauf P, Frič V, Elkalaf M, Urban T, Anděl M, Trnka J, Thoresen GH, 
Duška F. Mitochondrial pathogenesis of propofol infusion syndrome in an in vitro model of human 
skeletal muscle. Emerging Concepts in Mitochondrial Biology, Weizmann Institute of Science, 
Rehovot, Israel, February 4-8, 2018. 
Krajčová A, Waldauf P, Urban U, Džupa V, Duška F. Mitochondriální patogeneze syndromu 
propofolové infuze v in vitro modelu lidského kosterního svalu. XXIV. Kongres České společnosti 
anesteziologie, resuscitace a intenzivní medicíny, Brno, 7. - 9. září, 2017. 
 
20.1.3 Publications with IF non-related to the thesis 
Krajčová A, Megvinet D, Urban T, Waldauf P, Hlavička J, Budera P, Janoušek L, Pokorná E, Duška F. 
High resolution respirometry to assess function of mitochondria in native homogenates of human 
heart muscle. Circ Res (under review) 
98 
 
Jiroutková K, Krajčová A, Žiak J, Fric M, Gojda J, Džupa V, Kalous M, Tůmová J, Trnka J, Duška F. 
Mitochondrial Function in an In Vitro Model of Skeletal Muscle of Patients With Protracted Critical 
Illness and Intensive Care Unit-Acquired Weakness. J Parenter Enteral Nutr. 2016 Jun 29.  
Jiroutková K, Krajčová A, Ziak J, Fric M, Waldauf P, Džupa V, Gojda J, Němcova-Fürstová V, Kovář 
J, Elkalaf M, Trnka J, Duška F. Mitochondrial function in skeletal muscle of patients with protracted 
critical illness and ICU-acquired weakness. Crit Care. 24;19(1):448. (IF = 4.476) 
Ziak J, Krajcova A, Jiroutkova K, Nemcova V, Dzupa V, Duska F. Assessing the function of 
mitochondria in cytosolic context in human skeletal muscle: adopting high-resolution 
respirometry to homogenate of needle biopsy tissue samples. Mitochondrion. 2015 Mar;21:106-
12. (IF = 3.52) 
Krajcova A, Ziak J, Jiroutkova K, Patkova J, Elkalaf M, Dzupa V, Trnka J, Duska F. Normalizing 
glutamine concentration causes mitochondrial uncoupling in an in vitro model of human skeletal 
muscle. J Parenter Enteral Nutr. 2015 Feb;39(2):180-9. (IF = 3.14) 
Krajčová A, Matoušek V, Duška F. Mechanism of paracetamol-induced hypotension in critically ill 
patients: a prospective observational cross-over study. Aust Crit Care. 2013 Aug;26(3):136-41. (IF 
= 1.2) 
 
20.1.4 Publications without IF non-related to the thesis 
Gojda, Jan; Rossmeislová, Lenka; Tůmová, Jana; Krajčová, Adéla; Elkalaf, Moustafa; Žiak, Jakub; 
Jaček, Martin; Balušíková, Kamila; Duška, František; Trnka, Jan; Anděl, Michal. Postavení 
perkutánní biopsie kosterního svalu v diabetologickém výzkumu. Metodologický přehled. 
Diabetologie, metabolismus, endokrinologie, výživa. 2015, 18(4), 167‐176. 
Krajčová Adéla, Matoušek Vojtěch, Duška František. Mechanismus vzniku hypotenze po i. v. 
paracetamolu u kriticky nemocných. Anesteziologie a intenzivní medicína, 22, 2011, č. 5, s. 266-
271. 
 
20.1.5 Abstracts non-related to the thesis 
Krajcova A, Megvinet D, Waldauf P, Urban T, Budera P, Hlavicka J, Duska F, Drahota Z. Developing 
a method of assessing mitochondrial functions in homogenates of human heart muscle. 10th 
MitoEAGLE Workshop WG1-4, Obergurgl, Rakousko; 2017, Jul 27-30.  
99 
 
Krajčová A, Žiak J, Jiroutková K, Patková J, Elkalaf M, Džupa V, Trnka J, Duška F. Vliv glutaminu na 
proliferaci myoblastů a energetický metabolismus v in vitro modelu lidského kosterního svalu. 51. 
diabetologické dny, Luhačovice, 16. - 18. dubna 2015. 
Krajcova A, Ziak J, Jiroutkova K, Patkova J, Elkalaf M, Dzupa V, Trnka J, Duska F. Normalizing 
glutamine concentration causes mitochondrial uncoupling in an in vitro model of human skeletal 
muscle. Mitochondrial Disease: Translating biology into new treatments, Hinxton, Velká Británie, 
2–4 October 2013. 
Krajčová A, Matoušek V, Duška F. Mechanism of paracetamol-induced hypotension in critically ill 
patients International Student Congress of (bio)Medical Studies in Groningen, Netherlands, Jun 
2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
